@article{aby_cost-effectiveness_2022,
  title = {Cost-Effectiveness of {{Fecal Microbiota Transplantation}} for {{First Recurrent Clostridioides}} Difficile {{Infection}}},
  author = {Aby, Elizabeth S and Vaughn, Byron P and Enns, Eva A and Rajasingham, Radha},
  year = {2022},
  month = nov,
  journal = {Clinical Infectious Diseases},
  volume = {75},
  number = {9},
  pages = {1602--1609},
  issn = {1058-4838},
  doi = {10.1093/cid/ciac207},
  url = {https://doi.org/10.1093/cid/ciac207},
  urldate = {2023-05-04},
  abstract = {Both the American College of Gastroenterology and the Infectious Diseases Society of America (IDSA)/Society for Healthcare Epidemiology of America 2021 Clostridioides difficile infection (CDI) guidelines recommend fecal microbiota transplantation (FMT) for persons with multiple recurrent CDI. Emerging data suggest that FMT may have high cure rates when used for first recurrent CDI. The aim of this study was to assess the cost-effectiveness of FMT for first recurrent CDI.We developed a Markov model to simulate a cohort of patients presenting with initial CDI infection. The model estimated the costs, effectiveness, and cost-effectiveness of different CDI treatment regimens recommended in the 2021 IDSA guidelines, with the additional option of FMT for first recurrent CDI. The model includes stratification by the severity of initial infection, estimates of cure, recurrence, and mortality. Data sources were taken from IDSA guidelines and published literature on treatment outcomes. Outcome measures were quality-adjusted life-years (QALYs), costs, and incremental cost-effectiveness ratios (ICERs).When FMT is available for first recurrent CDI, the optimal cost-effective treatment strategy is fidaxomicin for initial nonsevere CDI, vancomycin for initial severe CDI, and FMT for first and subsequent recurrent CDI, with an ICER of \$27 135/QALY. In probabilistic sensitivity analysis at a \$100 000 cost-effectiveness threshold, FMT for first and subsequent CDI recurrence was cost-effective 90\% of the time given parameter uncertainty.FMT is a cost-effective strategy for first recurrent CDI. Prospective evaluation of FMT for first recurrent CDI is warranted to determine the efficacy and risk of recurrence.},
  file = {/Users/sovacool/Documents/Zotero/storage/ZXW9K8I3/Aby et al_2022_Cost-effectiveness of Fecal Microbiota Transplantation for First Recurrent.pdf;/Users/sovacool/Documents/Zotero/storage/TZVT3ZPB/6547272.html}
}

@article{altmann_permutation_2010,
  title = {Permutation Importance: A Corrected Feature Importance Measure},
  shorttitle = {Permutation Importance},
  author = {Altmann, Andr{\'e} and Tolo{\c s}i, Laura and Sander, Oliver and Lengauer, Thomas},
  year = {2010},
  month = may,
  journal = {Bioinformatics},
  volume = {26},
  number = {10},
  pages = {1340--1347},
  issn = {1367-4803},
  doi = {10.1093/bioinformatics/btq134},
  url = {https://doi.org/10.1093/bioinformatics/btq134},
  urldate = {2022-03-12},
  abstract = {Motivation: In life sciences, interpretability of machine learning models is as important as their prediction accuracy. Linear models are probably the most frequently used methods for assessing feature relevance, despite their relative inflexibility. However, in the past years effective estimators of feature relevance have been derived for highly complex or non-parametric models such as support vector machines and RandomForest (RF) models. Recently, it has been observed that RF models are biased in such a way that categorical variables with a large number of categories are preferred.Results: In this work, we introduce a heuristic for normalizing feature importance measures that can correct the feature importance bias. The method is based on repeated permutations of the outcome vector for estimating the distribution of measured importance for each variable in a non-informative setting. The P-value of the observed importance provides a corrected measure of feature importance. We apply our method to simulated data and demonstrate that (i) non-informative predictors do not receive significant P-values, (ii) informative variables can successfully be recovered among non-informative variables and (iii) P-values computed with permutation importance (PIMP) are very helpful for deciding the significance of variables, and therefore improve model interpretability. Furthermore, PIMP was used to correct RF-based importance measures for two real-world case studies. We propose an improved RF model that uses the significant variables with respect to the PIMP measure and show that its prediction accuracy is superior to that of other existing models.Availability: R code for the method presented in this article is available at http://www.mpi-inf.mpg.de/{$\sim$}altmann/download/PIMP.RContact:altmann@mpi-inf.mpg.de, laura.tolosi@mpi-inf.mpg.deSupplementary information:Supplementary data are available at Bioinformatics online.},
  file = {/Users/sovacool/Documents/Zotero/storage/FQB6S8ZC/Altmann et al. - 2010 - Permutation importance a corrected feature importance measure.pdf}
}

@article{antharam_intestinal_2013,
  title = {Intestinal {{Dysbiosis}} and {{Depletion}} of {{Butyrogenic Bacteria}} in {{{\emph{Clostridium}}}}{\emph{ Difficile}} {{Infection}} and {{Nosocomial Diarrhea}}},
  author = {Antharam, Vijay C. and Li, Eric C. and Ishmael, Arif and Sharma, Anuj and Mai, Volker and Rand, Kenneth H. and Wang, Gary P.},
  year = {2013},
  month = sep,
  journal = {J Clin Microbiol},
  volume = {51},
  number = {9},
  pages = {2884--2892},
  issn = {0095-1137, 1098-660X},
  doi = {10.1128/JCM.00845-13},
  url = {https://journals.asm.org/doi/10.1128/JCM.00845-13},
  urldate = {2023-06-02},
  abstract = {ABSTRACT                            Clostridium difficile               infection (CDI) causes nearly half a million cases of diarrhea and colitis in the United States each year. Although the importance of the gut microbiota in               C. difficile               pathogenesis is well recognized, components of the human gut flora critical for colonization resistance are not known. Culture-independent high-density Roche 454 pyrosequencing was used to survey the distal gut microbiota for 39 individuals with CDI, 36 subjects with               C. difficile               -negative nosocomial diarrhea (CDN), and 40 healthy control subjects. A total of 526,071 partial 16S rRNA sequence reads of the V1 to V3 regions were aligned with 16S databases, identifying 3,531 bacterial phylotypes from 115 fecal samples. Genomic analysis revealed significant alterations of organism lineages in both the CDI and CDN groups, which were accompanied by marked decreases in microbial diversity and species richness driven primarily by a paucity of phylotypes within the               Firmicutes               phylum. Normally abundant gut commensal organisms, including the               Ruminococcaceae               and               Lachnospiraceae               families and butyrate-producing C2 to C4 anaerobic fermenters, were significantly depleted in the CDI and CDN groups. These data demonstrate associations between the depletion of               Ruminococcaceae               ,               Lachnospiraceae               , and butyrogenic bacteria in the gut microbiota and nosocomial diarrhea, including               C. difficile               infection. Mechanistic studies focusing on the functional roles of these organisms in diarrheal diseases and resistance against               C. difficile               colonization are warranted.},
  langid = {english},
  file = {/Users/sovacool/Documents/Zotero/storage/YCW2E2I6/Antharam et al. - 2013 - Intestinal Dysbiosis and Depletion of Butyrogenic .pdf}
}

@article{barron_intestinal_2022,
  title = {Intestinal {{Inflammation Reversibly Alters}} the {{Microbiota}} to {{Drive Susceptibility}} to {{Clostridioides}} Difficile {{Colonization}} in a {{Mouse Model}} of {{Colitis}}},
  author = {Barron, Madeline R. and Sovacool, Kelly L. and {Abernathy-Close}, Lisa and Vendrov, Kimberly C. and Standke, Alexandra K. and Bergin, Ingrid L. and Schloss, Patrick D. and Young, Vincent B.},
  year = {2022},
  month = jul,
  journal = {mBio},
  volume = {0},
  number = {0},
  pages = {e01904-22},
  publisher = {{American Society for Microbiology}},
  doi = {10.1128/mbio.01904-22},
  url = {https://journals.asm.org/doi/full/10.1128/mbio.01904-22},
  urldate = {2022-08-05},
  copyright = {All rights reserved},
  file = {/Users/sovacool/Library/CloudStorage/GoogleDrive-sovacool@umich.edu/Shared drives/umich-shared/Zotero/Barron_et_al_2022_mBio.pdf}
}

@article{baunwall_faecal_2020,
  title = {Faecal Microbiota Transplantation for Recurrent {{{\emph{Clostridioides}}}}{\emph{ Difficile}} Infection: {{An}} Updated Systematic Review and Meta-Analysis},
  shorttitle = {Faecal Microbiota Transplantation for Recurrent {{Clostridioides}} Difficile Infection},
  author = {Baunwall, Simon Mark Dahl and Lee, Mads Ming and Eriksen, Marcel Kj{\ae}rsgaard and Mullish, Benjamin H. and Marchesi, Julian R. and Dahlerup, Jens Frederik and Hvas, Christian Lodberg},
  year = {2020},
  month = dec,
  journal = {EClinicalMedicine},
  volume = {29--30},
  pages = {100642},
  issn = {2589-5370},
  doi = {10.1016/j.eclinm.2020.100642},
  url = {https://www.sciencedirect.com/science/article/pii/S2589537020303862},
  urldate = {2023-05-04},
  abstract = {Background Faecal microbiota transplantation (FMT) is effective for recurrent Clostridioides difficile infection (CDI), but inconsistent effect rates and uncertain evidence levels have warranted caution. To clarify, we aimed to establish the evidence of FMT for recurrent CDI, updated across different delivery methods, treatment regimens, and in comparison with standard antibiotics. Methods In this updated systematic review and meta-analysis, we searched PubMed, Scopus, Embase, Web of Science, Clinical Key, and Svemed+ for FMT literature published in English until November 11, 2019. We included observational and clinical trials with or without antibiotic comparators and excluded studies with below 8 weeks follow-up and fewer than 15 patients. The primary outcome was clinical outcome by week 8. We comprehensively extracted patient and procedural data. In a random-effects meta-analysis, we estimated the clinical effect for repeat or single FMT, different delivery methods, and versus antibiotics. We rated the evidence according to the Cochrane and GRADE methods. The PROSPERO preregistration number is CRD42020158112. Findings Of 1816 studies assessed, 45 studies were included. The overall clinical effect week 8 following repeat FMT (24 studies, 1855 patients) was 91\% (95\% CI: 89\textendash 94\%, I2=53\%) and 84\% (80\textendash 88\%, I2=86\%) following single FMT (43 studies, 2937 patients). Delivery by lower gastrointestinal endoscopy was superior to all other delivery methods, and repeat FMT significantly increased the treatment effect week 8 (P{$<$}0{$\cdot$}001). Compared with vancomycin, the number needed to treat (NNT) for repeat FMT was 1{$\cdot$}5 (1{$\cdot$}3\textendash 1{$\cdot$}9, P{$<$}0{$\cdot$}001) and 2.9 (1{$\cdot$}5\textendash 37{$\cdot$}1, P=0{$\cdot$}03) for single FMT. Repeat FMT had high quality of evidence. Interpretation High-quality evidence supports FMT is effective for recurrent CDI, but its effect varies with the delivery method and the number of administrations. The superior NNT for FMT compared with antibiotics suggests that patients may benefit from advancing FMT to all instances of recurrent CDI. Funding Innovation Fund Denmark (j.no. 8056-00006B).},
  langid = {english},
  keywords = {CDI,Clostridioides difficile,Clostridioides difficile infection,Fecal microbiota transplantation,FMT,Meta-analysis,Number needed to treat,Systematic review},
  file = {/Users/sovacool/Documents/Zotero/storage/6EBL6W8Z/Baunwall et al_2020_Faecal microbiota transplantation for recurrent Clostridioides difficile.pdf;/Users/sovacool/Documents/Zotero/storage/GGZUTE4Y/S2589537020303862.html}
}

@article{berkell_microbiota-based_2021,
  title = {Microbiota-Based Markers Predictive of Development of {{{\emph{Clostridioides}}}}{\emph{ Difficile}} Infection},
  author = {Berkell, Matilda and Mysara, Mohamed and Xavier, Basil Britto and {van Werkhoven}, Cornelis H. and Monsieurs, Pieter and Lammens, Christine and Ducher, Annie and Vehreschild, Maria J. G. T. and Goossens, Herman and {de Gunzburg}, Jean and Bonten, Marc J. M. and {Malhotra-Kumar}, Surbhi},
  year = {2021},
  month = apr,
  journal = {Nat Commun},
  volume = {12},
  number = {1},
  pages = {2241},
  publisher = {{Nature Publishing Group}},
  issn = {2041-1723},
  doi = {10.1038/s41467-021-22302-0},
  url = {https://www.nature.com/articles/s41467-021-22302-0},
  urldate = {2023-06-02},
  abstract = {Antibiotic-induced modulation of the intestinal microbiota can lead to Clostridioides difficile infection (CDI), which is associated with considerable morbidity, mortality, and healthcare-costs globally. Therefore, identification of markers predictive of CDI could substantially contribute to guiding therapy and decreasing the infection burden. Here, we analyze the intestinal microbiota of hospitalized patients at increased CDI risk in a prospective, 90-day cohort-study before and after antibiotic treatment and at diarrhea onset. We show that patients developing CDI already exhibit significantly lower diversity before antibiotic treatment and a distinct microbiota enriched in Enterococcus and depleted of Ruminococcus, Blautia, Prevotella and Bifidobacterium compared to non-CDI patients. We find that antibiotic treatment-induced dysbiosis is class-specific with beta-lactams further increasing enterococcal abundance. Our findings, validated in an independent prospective patient cohort developing CDI, can be exploited to enrich for high-risk patients in prospective clinical trials, and to develop predictive microbiota-based diagnostics for management of patients at risk for CDI.},
  copyright = {2021 The Author(s)},
  langid = {english},
  keywords = {Microbiome,Next-generation sequencing,Predictive markers},
  file = {/Users/sovacool/Documents/Zotero/storage/TXX7HXLL/Berkell et al_2021_Microbiota-based markers predictive of development of Clostridioides difficile.pdf}
}

@article{bishop_management_2023,
  title = {Management of {{{\emph{Clostridioides}}}}{\emph{ Difficile}} Infection in Adults and Challenges in Clinical Practice: Review and Comparison of Current {{IDSA}}/{{SHEA}}, {{ESCMID}} and {{ASID}} Guidelines},
  shorttitle = {Management of {{{\emph{Clostridioides}}}}{\emph{ Difficile}} Infection in Adults and Challenges in Clinical Practice},
  author = {Bishop, Emma Jane and Tiruvoipati, Ravindranath},
  year = {2023},
  month = jan,
  journal = {Journal of Antimicrobial Chemotherapy},
  volume = {78},
  number = {1},
  pages = {21--30},
  issn = {0305-7453, 1460-2091},
  doi = {10.1093/jac/dkac404},
  url = {https://academic.oup.com/jac/article/78/1/21/6849560},
  urldate = {2023-05-12},
  abstract = {Abstract             Clostridioides difficile infection (CDI) remains a significant clinical challenge both in the management of severe and severe-complicated disease and the prevention of recurrence. Guidelines released by the Infectious Diseases Society of America and Society for Healthcare Epidemiology of America (IDSA/SHEA) and ESCMID had some consensus as well as some discrepancies in disease severity classification and treatment recommendations. We review and compare the key clinical strategies from updated IDSA/SHEA, ESCMID and current Australasian guidelines for CDI management in adults and discuss relevant issues for clinicians, particularly in the management of severe-complicated infection.             Updated IDSA/SHEA and ESCMID guidelines now reflect the increased efficacy of fidaxomicin in preventing recurrence and have both promoted fidaxomicin to first-line therapy with an initial CDI episode in both non-severe and severe disease and endorsed the role of bezlotoxumab in the prevention of recurrent infection. Vancomycin remains acceptable therapy and metronidazole is not preferred. For severe-complicated infection the IDSA/SHEA recommends high-dose oral{$\mkern1mu\pm\mkern1mu$}rectal vancomycin and IV metronidazole, whilst in an important development, ESCMID has endorsed fidaxomicin and tigecycline as part of combination anti-CDI therapy, for the first time. The role of faecal microbiota transplantation (FMT) in second CDI recurrence is now clearer, but timing and mode of FMT in severe-complicated refractory disease still requires further study.},
  langid = {english},
  file = {/Users/sovacool/Documents/Zotero/storage/PUYL6F8F/Bishop and Tiruvoipati - 2023 - Management of Clostridioides difficile infe.pdf}
}

@book{borg_modern_1997,
  title = {Modern {{Multidimensional Scaling}}},
  author = {Borg, Ingwer and Groenen, Patrick},
  year = {1997},
  series = {Springer {{Series}} in {{Statistics}}},
  publisher = {{Springer New York}},
  address = {{New York, NY}},
  doi = {10.1007/978-1-4757-2711-1},
  url = {http://link.springer.com/10.1007/978-1-4757-2711-1},
  urldate = {2023-03-28},
  isbn = {978-1-4757-2713-5 978-1-4757-2711-1},
  langid = {english},
  file = {/Users/sovacool/Documents/Zotero/storage/UEIDNWFN/Borg and Groenen - 1997 - Modern Multidimensional Scaling.pdf}
}

@article{bray_ordination_1957,
  title = {An {{Ordination}} of the {{Upland Forest Communities}} of {{Southern Wisconsin}}},
  author = {Bray, J. Roger and Curtis, J. T.},
  year = {1957},
  month = feb,
  journal = {Ecological Monographs},
  volume = {27},
  number = {4},
  pages = {325--349},
  issn = {00129615},
  doi = {10.2307/1942268},
  url = {http://doi.wiley.com/10.2307/1942268},
  urldate = {2020-08-11},
  langid = {english},
  file = {/Users/sovacool/Library/CloudStorage/GoogleDrive-sovacool@umich.edu/Shared drives/umich-shared/Zotero/Bray_et_al_1957_Ecological_Monographs.pdf}
}

@article{buffie_precision_2015,
  title = {Precision Microbiome Reconstitution Restores Bile Acid Mediated Resistance to {{Clostridium}} Difficile},
  author = {Buffie, Charlie G. and Bucci, Vanni and Stein, Richard R. and McKenney, Peter T. and Ling, Lilan and Gobourne, Asia and No, Daniel and Liu, Hui and Kinnebrew, Melissa and Viale, Agnes and Littmann, Eric and {van den Brink}, Marcel R. M. and Jenq, Robert R. and Taur, Ying and Sander, Chris and Cross, Justin R. and Toussaint, Nora C. and Xavier, Joao B. and Pamer, Eric G.},
  year = {2015},
  month = jan,
  journal = {Nature},
  volume = {517},
  number = {7533},
  pages = {205--208},
  publisher = {{Nature Publishing Group}},
  issn = {1476-4687},
  doi = {10.1038/nature13828},
  url = {https://www.nature.com/articles/nature13828},
  urldate = {2023-06-02},
  abstract = {A fraction of the intestinal microbiota as precise as a single bacterial species confers infection resistance by synthesizing Clostridium difficile-inhibiting metabolites from host-derived bile salts.},
  copyright = {2014 Springer Nature Limited},
  langid = {english},
  keywords = {Clostridium difficile,Metagenomics,Microbial ecology},
  file = {/Users/sovacool/Documents/Zotero/storage/E5N8YPG3/Buffie et al_2015_Precision microbiome reconstitution restores bile acid mediated resistance to.pdf}
}

@article{cao_basis_2022,
  title = {Basis of Narrow-Spectrum Activity of Fidaxomicin on {{Clostridioides}} Difficile},
  author = {Cao, Xinyun and Boyaci, Hande and Chen, James and Bao, Yu and Landick, Robert and Campbell, Elizabeth A.},
  year = {2022},
  month = apr,
  journal = {Nature},
  volume = {604},
  number = {7906},
  pages = {541--545},
  publisher = {{Nature Publishing Group}},
  issn = {1476-4687},
  doi = {10.1038/s41586-022-04545-z},
  url = {https://www.nature.com/articles/s41586-022-04545-z},
  urldate = {2023-02-07},
  abstract = {Fidaxomicin (Fdx) is widely used to treat Clostridioides difficile (Cdiff) infections, but the molecular basis of its narrow-spectrum activity in the human gut microbiome remains unknown. Cdiff infections are a leading cause of nosocomial deaths1. Fidaxomicin, which inhibits RNA polymerase, targets Cdiff with minimal effects on gut commensals, reducing recurrence of Cdiff infection2,3. Here we present the cryo-electron microscopy structure of Cdiff RNA polymerase in complex with fidaxomicin and identify a crucial fidaxomicin-binding determinant of Cdiff RNA polymerase that is absent in most gut microbiota such as Proteobacteria and Bacteroidetes. By combining structural, biochemical, genetic and bioinformatic analyses, we establish that a single residue in Cdiff RNA polymerase is a sensitizing element for fidaxomicin narrow-spectrum activity. Our results provide a blueprint for targeted drug design against an important human pathogen.},
  copyright = {2022 The Author(s), under exclusive licence to Springer Nature Limited},
  langid = {english},
  keywords = {Antibiotics,Cryoelectron microscopy,Pathogens,Transcription},
  file = {/Users/sovacool/Documents/Zotero/storage/SF3Q8QIB/Cao et al_2022_Basis of narrow-spectrum activity of fidaxomicin on Clostridioides difficile.pdf}
}

@article{centers_for_disease_control_and_prevention_antibiotic_2019,
  title = {Antibiotic {{Resistance Threats}} in the {{United States}}, 2019},
  author = {{Centers for Disease Control {and} Prevention}},
  year = {2019},
  langid = {english},
  file = {/Users/sovacool/Documents/Zotero/storage/5YPHACTD/2019 - Antibiotic Resistance Threats in the United States.pdf}
}

@article{chakra_prediction_2012,
  title = {Prediction {{Tools}} for {{Unfavourable Outcomes}} in {{{\emph{Clostridium}}}}{\emph{ Difficile}} {{Infection}}: {{A Systematic Review}}},
  shorttitle = {Prediction {{Tools}} for {{Unfavourable Outcomes}} in {{Clostridium}} Difficile {{Infection}}},
  author = {Chakra, Claire Nour Abou and Pepin, Jacques and Valiquette, Louis},
  year = {2012},
  month = jan,
  journal = {PLOS ONE},
  volume = {7},
  number = {1},
  pages = {e30258},
  publisher = {{Public Library of Science}},
  issn = {1932-6203},
  doi = {10.1371/journal.pone.0030258},
  url = {https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0030258},
  urldate = {2023-06-05},
  abstract = {Context Identifying patients at risk for adverse outcomes of Clostridium difficile infection (CDI), including recurrence and death, will become increasingly important as novel therapies emerge, which are more effective than traditional approaches but very expensive. Clinical prediction rules (CPRs) can improve the accuracy of medical decision-making. Several CPRs have been developed for CDI, but none has gained a widespread acceptance. Methods We systematically reviewed studies describing the derivation or validation of CPRs for unfavourable outcomes of CDI, in medical databases (Medline, Embase, PubMed, Web of Science and Cochrane) and abstracts of conferences. Results Of 2945 titles and abstracts screened, 13 studies on the derivation of a CPR were identified: two on recurrences, five on complications (including mortality), five on mortality alone and one on response to treatment. Two studies on the validation of different severity indices were also retrieved. Most CPRs were developed as secondary analyses using cohorts assembled for other purposes. CPRs presented several methodological limitations that could explain their limited use in clinical practice. Except for leukocytosis, albumin and age, there was much heterogeneity in the variables used, and most studies were limited by small sample sizes. Eight models used a retrospective design. Only four studies reported the incidence of the outcome of interest, even if this is essential to evaluate the potential usefulness of a model in other populations. Only five studies performed multivariate analyses to adjust for confounders. Conclusions The lack of weighing variables, of validation, calibration and measures of reproducibility, the weak validities and performances when assessed, and the absence of sensitivity analyses, all led to suboptimal quality and debatable utility of those CPRs. Evidence-based tools developed through appropriate prospective cohorts would be more valuable for clinicians than empirically-developed CPRs.},
  langid = {english},
  keywords = {Albumins,Cancer risk factors,Clostridium difficile,Epidemiology,Infectious diseases,Medical risk factors,Multivariate analysis,Systematic reviews},
  file = {/Users/sovacool/Documents/Zotero/storage/69BG75W8/Chakra et al_2012_Prediction Tools for Unfavourable Outcomes in Clostridium difficile Infection.pdf}
}

@article{chakra_risk_2014,
  title = {Risk {{Factors}} for {{Recurrence}}, {{Complications}} and {{Mortality}} in {{{\emph{Clostridium}}}}{\emph{ Difficile}} {{Infection}}: {{A Systematic Review}}},
  shorttitle = {Risk {{Factors}} for {{Recurrence}}, {{Complications}} and {{Mortality}} in {{Clostridium}} Difficile {{Infection}}},
  author = {Chakra, Claire Nour Abou and Pepin, Jacques and Sirard, Stephanie and Valiquette, Louis},
  year = {2014},
  month = jun,
  journal = {PLOS ONE},
  volume = {9},
  number = {6},
  pages = {e98400},
  publisher = {{Public Library of Science}},
  issn = {1932-6203},
  doi = {10.1371/journal.pone.0098400},
  url = {https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0098400},
  urldate = {2023-05-09},
  abstract = {Background Clostridium difficile infection (CDI) can lead to complications, recurrence, and death. Numerous studies have assessed risk factors for these unfavourable outcomes, but systematic reviews or meta-analyses published so far were limited in scope or in quality. Methods A systematic review was completed according to PRISMA guidelines. An electronic search in five databases was performed. Studies published until October 2013 were included if risk factors for at least one CDI outcome were assessed with multivariate analyses. Results 68 studies were included: 24 assessed risk factors for recurrence, 18 for complicated CDI, 8 for treatment failure, and 30 for mortality. Most studies accounted for mortality in the definition of complicated CDI. Important variables were inconsistently reported, such as previous episodes and use of antibiotics. Substantial heterogeneity and methodological limitations were noted, mainly in the sample size, the definition of the outcomes and periods of follow-up, precluding a meta-analysis. Older age, use of antibiotics after diagnosis, use of proton pump inhibitors, and strain type were the most frequent risk factors for recurrence. Older age, leucocytosis, renal failure and co-morbidities were frequent risk factors for complicated CDI. When considered alone, mortality was associated with age, co-morbidities, hypo-albuminemia, leucocytosis, acute renal failure, and infection with ribotype 027. Conclusion Laboratory parameters currently used in European and American guidelines to define patients at risk of a complicated CDI are adequate. Strategies for the management of CDI should be tailored according to the age of the patient, biological markers of severity, and underlying co-morbidities.},
  langid = {english},
  keywords = {Antibiotics,Clostridium difficile,Creatinine,Database searching,Medical risk factors,Metaanalysis,Multivariate analysis,Systematic reviews},
  file = {/Users/sovacool/Documents/Zotero/storage/WL4CDSJT/Chakra et al_2014_Risk Factors for Recurrence, Complications and Mortality in Clostridium.pdf}
}

@article{cohen_clinical_2010,
  title = {Clinical Practice Guidelines for {{{\emph{Clostridium}}}}{\emph{ Difficile}} Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of {{America}} ({{SHEA}}) and the Infectious Diseases Society of {{America}} ({{IDSA}})},
  shorttitle = {Clinical Practice Guidelines for {{Clostridium}} Difficile Infection in Adults},
  author = {Cohen, Stuart H. and Gerding, Dale N. and Johnson, Stuart and Kelly, Ciaran P. and Loo, Vivian G. and McDonald, L. Clifford and Pepin, Jacques and Wilcox, Mark H. and {Society for Healthcare Epidemiology of America} and {Infectious Diseases Society of America}},
  year = {2010},
  month = may,
  journal = {Infect Control Hosp Epidemiol},
  volume = {31},
  number = {5},
  pages = {431--455},
  issn = {1559-6834},
  doi = {10.1086/651706},
  abstract = {Since publication of the Society for Healthcare Epidemiology of America position paper on Clostridium difficile infection in 1995, significant changes have occurred in the epidemiology and treatment of this infection. C. difficile remains the most important cause of healthcare-associated diarrhea and is increasingly important as a community pathogen. A more virulent strain of C. difficile has been identified and has been responsible for more-severe cases of disease worldwide. Data reporting the decreased effectiveness of metronidazole in the treatment of severe disease have been published. Despite the increasing quantity of data available, areas of controversy still exist. This guideline updates recommendations regarding epidemiology, diagnosis, treatment, and infection control and environmental management.},
  langid = {english},
  pmid = {20307191},
  keywords = {Adult,Clostridioides difficile,Clostridium Infections,Cross Infection,{Enterocolitis, Pseudomembranous},Humans,Infection Control}
}

@article{cole_ribosomal_2014,
  title = {Ribosomal {{Database Project}}: Data and Tools for High Throughput {{rRNA}} Analysis},
  shorttitle = {Ribosomal {{Database Project}}},
  author = {Cole, James R. and Wang, Qiong and Fish, Jordan A. and Chai, Benli and McGarrell, Donna M. and Sun, Yanni and Brown, C. Titus and {Porras-Alfaro}, Andrea and Kuske, Cheryl R. and Tiedje, James M.},
  year = {2014},
  month = jan,
  journal = {Nucl. Acids Res.},
  volume = {42},
  number = {D1},
  pages = {D633-D642},
  issn = {0305-1048, 1362-4962},
  doi = {10.1093/nar/gkt1244},
  url = {https://academic.oup.com/nar/article-lookup/doi/10.1093/nar/gkt1244},
  urldate = {2021-03-05},
  abstract = {Ribosomal Database Project (RDP; http://rdp.cme. msu.edu/) provides the research community with aligned and annotated rRNA gene sequence data, along with tools to allow researchers to analyze their own rRNA gene sequences in the RDP framework. RDP data and tools are utilized in fields as diverse as human health, microbial ecology, environmental microbiology, nucleic acid chemistry, taxonomy and phylogenetics. In addition to aligned and annotated collections of bacterial and archaeal small subunit rRNA genes, RDP now includes a collection of fungal large subunit rRNA genes. RDP tools, including Classifier and Aligner, have been updated to work with this new fungal collection. The use of high-throughput sequencing to characterize environmental microbial populations has exploded in the past several years, and as sequence technologies have improved, the sizes of environmental datasets have increased. With release 11, RDP is providing an expanded set of tools to facilitate analysis of high-throughput data, including both single-stranded and paired-end reads. In addition, most tools are now available as open source packages for download and local use by researchers with high-volume needs or who would like to develop custom analysis pipelines.},
  langid = {english},
  file = {/Users/sovacool/Library/CloudStorage/GoogleDrive-sovacool@umich.edu/Shared drives/umich-shared/Zotero/Cole_et_al_2014_Nucl._Acids_Res..pdf}
}

@article{collins_transparent_2015,
  title = {Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis ({{TRIPOD}}): The {{TRIPOD Statement}}},
  shorttitle = {Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis ({{TRIPOD}})},
  author = {Collins, Gary S. and Reitsma, Johannes B. and Altman, Douglas G. and Moons, Karel GM},
  year = {2015},
  month = jan,
  journal = {BMC Medicine},
  volume = {13},
  number = {1},
  pages = {1},
  issn = {1741-7015},
  doi = {10.1186/s12916-014-0241-z},
  url = {https://doi.org/10.1186/s12916-014-0241-z},
  urldate = {2023-05-24},
  abstract = {Prediction models are developed to aid health care providers in estimating the probability or risk that a specific disease or condition is present (diagnostic models) or that a specific event will occur in the future (prognostic models), to inform their decision making. However, the overwhelming evidence shows that the quality of reporting of prediction model studies is poor. Only with full and clear reporting of information on all aspects of a prediction model can risk of bias and potential usefulness of prediction models be adequately assessed. The Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD) Initiative developed a set of recommendations for the reporting of studies developing, validating, or updating a prediction model, whether for diagnostic or prognostic purposes. This article describes how the TRIPOD Statement was developed. An extensive list of items based on a review of the literature was created, which was reduced after a Web-based survey and revised during a 3-day meeting in June 2011 with methodologists, health care professionals, and journal editors. The list was refined during several meetings of the steering group and in e-mail discussions with the wider group of TRIPOD contributors. The resulting TRIPOD Statement is a checklist of 22 items, deemed essential for transparent reporting of a prediction model study. The TRIPOD Statement aims to improve the transparency of the reporting of a prediction model study regardless of the study methods used. The TRIPOD Statement is best used in conjunction with the TRIPOD explanation and elaboration document. To aid the editorial process and readers of prediction model studies, it is recommended that authors include a completed checklist in their submission (also available at www.tripod-statement.org).},
  keywords = {Diagnostic,Model development,Prediction models,Prognostic,Reporting,Transparency,Validation},
  file = {/Users/sovacool/Documents/Zotero/storage/UU58SJI2/Collins et al_2015_Transparent reporting of a multivariable prediction model for individual.pdf;/Users/sovacool/Documents/Zotero/storage/I86R5UX9/s12916-014-0241-z.html}
}

@article{cook_number_1995,
  title = {The Number Needed to Treat: A Clinically Useful Measure of Treatment Effect},
  shorttitle = {The Number Needed to Treat},
  author = {Cook, Richard J. and Sackett, David L.},
  year = {1995},
  month = feb,
  journal = {BMJ},
  volume = {310},
  number = {6977},
  pages = {452--454},
  publisher = {{British Medical Journal Publishing Group}},
  issn = {0959-8138, 1468-5833},
  doi = {10.1136/bmj.310.6977.452},
  url = {https://www.bmj.com/content/310/6977/452},
  urldate = {2023-06-01},
  abstract = {The relative benefit of an active treatment over a control is usually expressed as the relative risk, the relative risk reduction, or the odds ratio. These measures are used extensively in both clinical and epidemiological investigations. For clinical decision making, however, it is more meaningful to use the measure ``number needed to treat.'' This measure is calculated on the inverse of the absolute risk reduction. It has the advantage that it conveys both statistical and clinical significance to the doctor. Furthermore, it can be used to extrapolate published findings to a patient at an arbitrary specified baseline risk when the relative risk reduction associated with treatment is constant for all levels of risk. More emphasis is now being put on effective use of biomedical literature to guide clinical treatment. As a result accessing, critically appraising, and incorporating the results of clinical investigations into clinical practice are becoming higher priorities for doctors and medical students.1 A pivotal step in translating clinical research into practice is the summarisation of data from randomised trials in terms of measures of effect that can be readily appreciated by doctors and other carers. Various measures of the effect of treatment are used in analysing results. Each measure has its own interpretation and statistical properties that make it suitable for some applications but perhaps not for others. We describe here a new measure referred to as number needed to treat2 and a simple method of adopting this approach to individual patients at different levels of risk. Consider a parallel group study in which patients are randomised to either an active treatment or a placebo control arm, are followed for a fixed amount of time, and are observed to experience a binary response to treatment (event/no event). We assume here that the events are adverse, and \ldots},
  chapter = {Education and debate},
  copyright = {\textcopyright{} 1995 BMJ Publishing Group Ltd.},
  langid = {english},
  pmid = {7873954},
  file = {/Users/sovacool/Documents/Zotero/storage/YHUAFGJF/Cook_Sackett_1995_The number needed to treat.pdf;/Users/sovacool/Documents/Zotero/storage/2RRE8C25/452.html}
}

@article{de_la_villa_real-world_2023,
  title = {Real-World {{Use}} of {{Bezlotoxumab}} and {{Fecal Microbiota Transplantation}} for the {{Treatment}} of {{Clostridioides}} Difficile {{Infection}}},
  author = {{de la Villa}, Sof{\'i}a and Herrero, Sergio and Mu{\~n}oz, Patricia and Rodr{\'i}guez, Carmen and Valerio, Maricela and Reigadas, Elena and {\'A}lvarez-Ur{\'i}a, Ana and Alcal{\'a}, Luis and Mar{\'i}n, Mercedes and Olmedo, Mar{\'i}a and Kestler, Martha and Chamorro, Esther and Bouza, Emilio},
  year = {2023},
  month = feb,
  journal = {Open Forum Infectious Diseases},
  volume = {10},
  number = {2},
  pages = {ofad028},
  issn = {2328-8957},
  doi = {10.1093/ofid/ofad028},
  url = {https://doi.org/10.1093/ofid/ofad028},
  urldate = {2023-05-08},
  abstract = {We aimed to describe the frequency of use and effectiveness of bezlotoxumab (BZX) and fecal microbiota transplantation (FMT) in patients with Clostridioides difficile infection (CDI) in real-world practice.This was a retrospective study conducted in a university hospital in which adult patients treated with BZX or FMT from January 2018 to April 2021 were included. The primary objective was to evaluate the effectiveness of BZX and FMT in preventing early (within 8 weeks) and late (within 1 year) CDI recurrences (rCDI). A multivariate analysis of risk factors for early recurrence was performed.Of 1377 consecutive CDI episodes, 117 (8.5\%) received BZX or FMT, with full information available for 100 of the episodes: 51 received BZX, and 49 received FMT. BZX was used mostly in immunosuppressed patients (66.7\%) and in first episodes or first recurrences in 70.6\% of the cases. FMT was prescribed only in CDI recurrences. Despite the different conditions of the patients, there were no significant differences between BZX and FMT in preventing early rCDI (19.6\% vs 24.5\%; P = .55) or late rCDI (9.8\% vs 18.4\%; P = .31). In the multivariate analysis, risk factors for recurrence were presence of {$\geq$}2 previous rCDI episodes (odds ratio [OR], 2.90; 95\% CI, 1.03\textendash 8.63) and use of non-CDI antibiotics (OR, 3.45; 95\% CI, 1.24\textendash 9.57).BZX and FMT were infrequently used in real-world practice. Both treatments had similar effectiveness in preventing CDI recurrence despite their application to different populations.},
  file = {/Users/sovacool/Documents/Zotero/storage/QBCKYUMA/de la Villa et al_2023_Real-world Use of Bezlotoxumab and Fecal Microbiota Transplantation for the.pdf;/Users/sovacool/Documents/Zotero/storage/GLCFWDPM/7005371.html}
}

@article{dieterle_novel_2019,
  title = {Novel Therapies and Preventative Strategies for Primary and Recurrent {{{\emph{Clostridium}}}}{\emph{ Difficile}} Infections},
  author = {Dieterle, Michael G. and Rao, Krishna and Young, Vincent B.},
  year = {2019},
  journal = {Annals of the New York Academy of Sciences},
  volume = {1435},
  number = {1},
  pages = {110--138},
  issn = {1749-6632},
  doi = {10.1111/nyas.13958},
  url = {https://onlinelibrary.wiley.com/doi/abs/10.1111/nyas.13958},
  urldate = {2023-05-09},
  abstract = {Clostridium difficile is the leading infectious cause of antibiotic-associated diarrhea and colitis. C. difficile infection (CDI) places a heavy burden on the healthcare system, with nearly half a million infections yearly and an approximate 20\% recurrence risk after successful initial therapy. The high incidence has driven new research on improved prevention such as the emerging use of probiotics, intestinal microbiome manipulation during antibiotic therapies, vaccinations, and newer antibiotics that reduce the disruption of the intestinal microbiome. While the treatment of acute C. difficile is effective in most patients, it can be further optimized by adjuvant therapies that improve the initial treatment success and decrease the risk of subsequent recurrence. Finally, the high risk of recurrence has led to multiple emerging therapies that target toxin activity, recovery of the intestinal microbial community, and elimination of latent C. difficile in the intestine. In summary, CDIs illustrate the complex interaction among host physiology, microbial community, and pathogen that requires specific therapies to address each of the factors leading to primary infection and recurrence.},
  langid = {english},
  keywords = {antibiotics,Clostridium difficile infection,emerging therapies,microbiome,microbiota},
  file = {/Users/sovacool/Documents/Zotero/storage/T2SIN7L7/Dieterle et al_2019_Novel therapies and preventative strategies for primary and recurrent.pdf;/Users/sovacool/Documents/Zotero/storage/96UTC8TX/nyas.html}
}

@article{dieterle_systemic_2020,
  title = {Systemic {{Inflammatory Mediators Are Effective Biomarkers}} for {{Predicting Adverse Outcomes}} in {{{\emph{Clostridioides}}}}{\emph{ Difficile}} {{Infection}}},
  author = {Dieterle, Michael G. and Putler, Rosemary and Perry, D. Alexander and Menon, Anitha and {Abernathy-Close}, Lisa and Perlman, Naomi S. and Penkevich, Aline and Standke, Alex and Keidan, Micah and Vendrov, Kimberly C. and Bergin, Ingrid L. and Young, Vincent B. and Rao, Krishna},
  year = {2020},
  month = may,
  journal = {mBio},
  volume = {11},
  number = {3},
  pages = {e00180-20},
  doi = {10.1128/mBio.00180-20},
  url = {https://journals.asm.org/doi/full/10.1128/mBio.00180-20},
  urldate = {2023-04-05},
  abstract = {Clostridioides difficile infection (CDI) can result in severe disease and death, with no accurate models that allow for early prediction of adverse outcomes. To address this need, we sought to develop serum-based biomarker models to predict CDI outcomes. We prospectively collected sera {$\leq$}48 h after diagnosis of CDI in two cohorts. Biomarkers were measured with a custom multiplex bead array assay. Patients were classified using IDSA severity criteria and the development of disease-related complications (DRCs), which were defined as ICU admission, colectomy, and/or death attributed to CDI. Unadjusted and adjusted models were built using logistic and elastic net modeling. The best model for severity included procalcitonin (PCT) and hepatocyte growth factor (HGF) with an area (AUC) under the receiver operating characteristic (ROC) curve of 0.74 (95\% confidence interval, 0.67 to 0.81). The best model for 30-day mortality included interleukin-8 (IL-8), PCT, CXCL-5, IP-10, and IL-2R{$\alpha$} with an AUC of 0.89 (0.84 to 0.95). The best model for DRCs included IL-8, procalcitonin, HGF, and IL-2R{$\alpha$} with an AUC of 0.84 (0.73 to 0.94). To validate our models, we employed experimental infection of mice with C. difficile. Antibiotic-treated mice were challenged with C. difficile and a similar panel of serum biomarkers was measured. Applying each model to the mouse cohort of severe and nonsevere CDI revealed AUCs of 0.59 (0.44 to 0.74), 0.96 (0.90 to 1.0), and 0.89 (0.81 to 0.97). In both human and murine CDI, models based on serum biomarkers predicted adverse CDI outcomes. Our results support the use of serum-based biomarker panels to inform Clostridioides difficile infection treatment. IMPORTANCE Each year in the United States, Clostridioides difficile causes nearly 500,000 gastrointestinal infections that range from mild diarrhea to severe colitis and death. The ability to identify patients at increased risk for severe disease or mortality at the time of diagnosis of C. difficile infection (CDI) would allow clinicians to effectively allocate disease modifying therapies. In this study, we developed models consisting of only a small number of serum biomarkers that are capable of predicting both 30-day all-cause mortality and adverse outcomes of patients at time of CDI diagnosis. We were able to validate these models through experimental mouse infection. This provides evidence that the biomarkers reflect the underlying pathophysiology and that our mouse model of CDI reflects the pathogenesis of human infection. Predictive models can not only assist clinicians in identifying patients at risk for severe CDI but also be utilized for targeted enrollment in clinical trials aimed at reduction of adverse outcomes from severe CDI.},
  file = {/Users/sovacool/Documents/Zotero/storage/3ECIMNMH/Dieterle et al. - 2020 - Systemic Inflammatory Mediators Are Effective Biom.pdf}
}

@article{fawcett_introduction_2006,
  title = {An Introduction to {{ROC}} Analysis},
  author = {Fawcett, Tom},
  year = {2006},
  month = jun,
  journal = {Pattern Recognition Letters},
  volume = {27},
  number = {8},
  pages = {861--874},
  issn = {01678655},
  doi = {10.1016/j.patrec.2005.10.010},
  url = {https://linkinghub.elsevier.com/retrieve/pii/S016786550500303X},
  urldate = {2023-03-28},
  abstract = {Receiver operating characteristics (ROC) graphs are useful for organizing classifiers and visualizing their performance. ROC graphs are commonly used in medical decision making, and in recent years have been used increasingly in machine learning and data mining research. Although ROC graphs are apparently simple, there are some common misconceptions and pitfalls when using them in practice. The purpose of this article is to serve as an introduction to ROC graphs and as a guide for using them in research.},
  langid = {english},
  file = {/Users/sovacool/Documents/Zotero/storage/U4KWXFD5/Fawcett - 2006 - An introduction to ROC analysis.pdf}
}

@article{feuerstadt_burden_2023,
  title = {The Burden of {{CDI}} in the {{United States}}: A Multifactorial Challenge},
  shorttitle = {The Burden of {{CDI}} in the {{United States}}},
  author = {Feuerstadt, Paul and Theriault, Nicolette and Tillotson, Glenn},
  year = {2023},
  month = mar,
  journal = {BMC Infectious Diseases},
  volume = {23},
  number = {1},
  pages = {132},
  issn = {1471-2334},
  doi = {10.1186/s12879-023-08096-0},
  url = {https://doi.org/10.1186/s12879-023-08096-0},
  urldate = {2023-06-04},
  abstract = {Clostridioides difficile infection (CDI) affects approximately 500,000 patients annually in the United States, of these around 30,000 will die. CDI carries significant burdens including clinical, social and economic. While healthcare-associated CDI has declined in recent years, community-associated CDI is on the rise. Many patients are also impacted by recurrent C. difficile infections (rCDI); up to 35\% of index CDI will recur and of these up to 60\% will further recur with multiple recurrences observed. The range of outcomes adversely affected by rCDI is significant and current standard of care does not alter these recurrence rates due to the damaged gut microbiome and subsequent dysbiosis. The clinical landscape of CDI is changing, we discuss the impact of CDI, rCDI, and the wide range of financial, social, and clinical outcomes by which treatments should be evaluated.},
  keywords = {Clostridioides difficile infection,Community-acquired,Healthcare burden,Healthcare-associated,Quality of life,Recurrent C. difficile infections},
  file = {/Users/sovacool/Documents/Zotero/storage/4S4TFDNX/Feuerstadt et al_2023_The burden of CDI in the United States.pdf;/Users/sovacool/Documents/Zotero/storage/DVX4HGPP/s12879-023-08096-0.html}
}

@article{fischer_fecal_2017,
  title = {Fecal Microbiota Transplant in Severe and Severe-Complicated {{Clostridium}} Difficile: {{A}} Promising Treatment Approach},
  shorttitle = {Fecal Microbiota Transplant in Severe and Severe-Complicated {{Clostridium}} Difficile},
  author = {Fischer, Monika and Sipe, Brian and Cheng, Yao-Wen and Phelps, Emmalee and Rogers, Nicholas and Sagi, Sashidhar and Bohm, Matthew and Xu, Huiping and Kassam, Zain},
  year = {2017},
  month = may,
  journal = {Gut Microbes},
  volume = {8},
  number = {3},
  pages = {289--302},
  publisher = {{Taylor \& Francis}},
  issn = {1949-0976},
  doi = {10.1080/19490976.2016.1273998},
  url = {https://doi.org/10.1080/19490976.2016.1273998},
  urldate = {2023-05-04},
  abstract = {Severe and severe-complicated Clostridium difficile infection (CDI) is associated with high morbidity and mortality. Colectomy is standard of care; however, post-surgical mortality rates approach 50\%. Case reports suggest fecal microbiota transplant (FMT) is a promising treatment of severe and severe-complicated disease but there is a paucity of data. Here, we present a single center experience with a novel sequential FMT protocol for patients refractory to maximal medical therapy. This approach consists of at least one FMT delivered via colonoscopy with criteria for repeat FMT and continued vancomycin therapy based on clinical response and pseudomembranes. Our cohort included 57 consecutive inpatients diagnosed with severe or severe-complicated CDI and treated with FMT. Overall, 91\% (52/57) experienced clinical cure at 1 month with a 100\% cure rate among severe CDI (n = 19) patients and an 87\% cure rate for severe-complicated CDI (n = 33) patients. For the cohort, the survival rate was 94.7\% at 1 month and 78.6\% at 3 months. There were no serious adverse events related to FMT including no procedure-related complications or perforation. There was no difference in outcome between fresh or frozen fecal material. Sequential FMT for inpatients with severe or severe-complicated CDI is promising and may be preferred over colectomy in certain patients.},
  pmid = {28001467},
  keywords = {Fecal microbiota transplant,FMT,fulminant C. difficile,pseudomembranes,severe and complicated C. difficile infection,severe C. difficile infection},
  file = {/Users/sovacool/Documents/Zotero/storage/X5HRADWQ/Fischer et al_2017_Fecal microbiota transplant in severe and severe-complicated Clostridium.pdf}
}

@article{fishbein_randomized_2021,
  title = {Randomized {{Controlled Trial}} of {{Oral Vancomycin Treatment}} in {{Clostridioides}} Difficile-{{Colonized Patients}}},
  author = {Fishbein, Skye R. S. and Hink, Tiffany and Reske, Kimberly A. and Cass, Candice and Struttmann, Emily and Iqbal, Zainab Hassan and Seiler, Sondra and Kwon, Jennie H. and Burnham, Carey-Ann D. and Dantas, Gautam and Dubberke, Erik R.},
  year = {2021},
  month = jan,
  journal = {mSphere},
  volume = {6},
  number = {1},
  pages = {10.1128/msphere.00936-20},
  publisher = {{American Society for Microbiology}},
  doi = {10.1128/msphere.00936-20},
  url = {https://journals.asm.org/doi/full/10.1128/mSphere.00936-20},
  urldate = {2023-06-03},
  abstract = {Clostridioides difficile infection (CDI) is most commonly diagnosed using nucleic acid amplification tests (NAAT); the low positive predictive value of these assays results in patients colonized with C. difficile unnecessarily receiving CDI treatment antibiotics. The risks and benefits of antibiotic treatment in individuals with such cases are unknown. Fecal samples of NAAT-positive, toxin enzyme immunoassay (EIA)-negative patients were collected before, during, and after randomization to vancomycin (n\,=\,8) or placebo (n\,=\,7). C. difficile and antibiotic-resistant organisms (AROs) were selectively cultured from fecal and environmental samples. Shotgun metagenomics and comparative isolate genomics were used to understand the impact of oral vancomycin on the microbiome and environmental contamination. Overall, 80\% of placebo patients and 71\% of vancomycin patients were colonized with C. difficile posttreatment. One person randomized to placebo subsequently received treatment for CDI. In the vancomycin-treated group, beta-diversity (P\,=\,0.0059) and macrolide-lincosamide-streptogramin (MLS) resistance genes (P\,=\,0.037) increased after treatment; C. difficile and vancomycin-resistant enterococci (VRE) environmental contamination was found in 53\% of patients and 26\% of patients, respectively. We found that vancomycin alters the gut microbiota, does not permanently clear C. difficile, and is associated with VRE colonization/environmental contamination. (This study has been registered at ClinicalTrials.gov under registration no. NCT03388268.) IMPORTANCE A gold standard diagnostic for Clostridioides difficile infection (CDI) does not exist. An area of controversy is how to manage patients whose stool tests positive by nucleic acid amplification tests but negative by toxin enzyme immunoassay. Existing data suggest most of these patients do not have CDI, but most are treated with oral vancomycin. Potential benefits to treatment include a decreased risk for adverse outcomes if the patient does have CDI and the potential to decrease C. difficile shedding/transmission. However, oral vancomycin perturbs the intestinal microbiota and promotes antibiotic-resistant organism colonization/transmission. We conducted a double-blinded randomized controlled trial to assess the risk-benefit of oral vancomycin treatment in this population. Oral vancomycin did not result in long-term clearance of C. difficile, perturbed the microbiota, and was associated with colonization/shedding of vancomycin-resistant enterococci. This work underscores the need to better understand this population of patients in the context of C. difficile/ARO-related outcomes and transmission.},
  file = {/Users/sovacool/Documents/Zotero/storage/79FU75RK/Fishbein et al_2021_Randomized Controlled Trial of Oral Vancomycin Treatment in Clostridioides.pdf}
}

@article{gandhi_inpatient_2023,
  title = {Inpatient {{Adult}} and {{Pediatric Clostridium}} Difficile {{Infection Guideline}}},
  author = {Gandhi, Tejal and Rao, Krishna},
  year = {2023},
  langid = {english},
  file = {/Users/sovacool/Documents/Zotero/storage/8EX7MZ2S/Patrick - 2023 - Inpatient Adult and Pediatric Clostridium difficil.pdf}
}

@article{guh_clostridioides_2018,
  title = {{\emph{Clostridioides Difficile}} {{Infection}}},
  author = {Guh, Alice Y. and Kutty, Preeta K.},
  year = {2018},
  month = oct,
  journal = {Ann Intern Med},
  volume = {169},
  number = {7},
  pages = {ITC49-ITC64},
  publisher = {{American College of Physicians}},
  issn = {0003-4819},
  doi = {10.7326/AITC201810020},
  url = {https://www.acpjournals.org/doi/10.7326/AITC201810020},
  urldate = {2021-08-27},
  file = {/Users/sovacool/Library/CloudStorage/GoogleDrive-sovacool@umich.edu/Shared drives/umich-shared/Zotero/Guh_et_al_2018_Ann_Intern_Med.pdf}
}

@article{guh_trends_2020,
  title = {Trends in {{U}}.{{S}}. {{Burden}} of {{{\emph{Clostridioides}}}}{\emph{ Difficile}} {{Infection}} and {{Outcomes}}},
  author = {Guh, Alice Y. and Mu, Yi and Winston, Lisa G. and Johnston, Helen and Olson, Danyel and Farley, Monica M. and Wilson, Lucy E. and Holzbauer, Stacy M. and Phipps, Erin C. and Dumyati, Ghinwa K. and Beldavs, Zintars G. and Kainer, Marion A. and Karlsson, Maria and Gerding, Dale N. and McDonald, L. Clifford},
  year = {2020},
  month = apr,
  journal = {N Engl J Med},
  volume = {382},
  number = {14},
  pages = {1320--1330},
  publisher = {{Massachusetts Medical Society}},
  issn = {0028-4793},
  doi = {10.1056/NEJMoa1910215},
  url = {https://www.nejm.org/doi/10.1056/NEJMoa1910215},
  urldate = {2023-06-04},
  file = {/Users/sovacool/Documents/Zotero/storage/R3X3FH4W/Guh et al_2020_Trends in U.pdf}
}

@article{gupta_economic_2021,
  title = {Economic Burden and Cost-Effectiveness of Therapies for {{{\emph{Clostridiodes}}}}{\emph{ Difficile}} Infection: A Narrative Review},
  shorttitle = {Economic Burden and Cost-Effectiveness of Therapies for {{Clostridiodes}} Difficile Infection},
  author = {Gupta, Akshita and Ananthakrishnan, Ashwin N.},
  year = {2021},
  month = jan,
  journal = {Therap Adv Gastroenterol},
  volume = {14},
  pages = {17562848211018654},
  publisher = {{SAGE Publications Ltd STM}},
  issn = {1756-2848},
  doi = {10.1177/17562848211018654},
  url = {https://doi.org/10.1177/17562848211018654},
  urldate = {2023-04-12},
  abstract = {Clostridioides difficile is the most common cause of healthcare-associated diarrhea. Disease complications as well as recurrent infections contribute significantly to morbidity and mortality. Over the past decades, there has been a rapid increase in the incidence of C. difficile infection (CDI), with a rise in the number of community-acquired cases. CDI has a profound economic impact on both the healthcare system and patients, secondary to recurrences, hospitalization, prolonged length of stay, cost of treatment, and indirect societal costs. With emergence of newer treatment options, the standard of care is shifting from metronidazole and vancomycin towards fidaxomicin and fecal microbiota transplantation (FMT), which despite being more expensive, are more efficacious in preventing recurrences and hence overall are more beneficial forms of therapy per cost-effectiveness analyses. Data regarding preferred route of FMT, timing of FMT, and non-conventional therapies such as bezlotoxumab is scant. There is a need for further studies to elucidate the true attributable costs of CDI as well as continued cost-effectiveness research to reduce the economic burden associated with the disease and improve clinical practice.},
  langid = {english},
  file = {/Users/sovacool/Documents/Zotero/storage/DDWWTWTG/Gupta_Ananthakrishnan_2021_Economic burden and cost-effectiveness of therapies for Clostridiodes difficile.pdf}
}

@article{hasegawa_protective_2012,
  title = {Protective {{Role}} of {{Commensals}} against {{{\emph{Clostridium}}}}{\emph{ Difficile}} {{Infection}} via an {{IL-1$\beta$}}\textendash{{Mediated Positive-Feedback Loop}}},
  author = {Hasegawa, Mizuho and Kamada, Nobuhiko and Jiao, Yizu and Liu, Meng Zhen and N{\'u}{\~n}ez, Gabriel and Inohara, Naohiro},
  year = {2012},
  month = sep,
  journal = {J.I.},
  volume = {189},
  number = {6},
  pages = {3085--3091},
  issn = {0022-1767, 1550-6606},
  doi = {10.4049/jimmunol.1200821},
  url = {http://www.jimmunol.org/lookup/doi/10.4049/jimmunol.1200821},
  urldate = {2022-01-11},
  langid = {english},
  file = {/Users/sovacool/Library/CloudStorage/GoogleDrive-sovacool@umich.edu/Shared drives/umich-shared/Zotero/Hasegawa_et_al_2012_J.I..pdf}
}

@article{he_practical_2019,
  title = {The Practical Implementation of Artificial Intelligence Technologies in Medicine},
  author = {He, Jianxing and Baxter, Sally L. and Xu, Jie and Xu, Jiming and Zhou, Xingtao and Zhang, Kang},
  year = {2019},
  month = jan,
  journal = {Nat Med},
  volume = {25},
  number = {1},
  pages = {30--36},
  publisher = {{Nature Publishing Group}},
  issn = {1546-170X},
  doi = {10.1038/s41591-018-0307-0},
  url = {https://www.nature.com/articles/s41591-018-0307-0},
  urldate = {2023-05-29},
  abstract = {The development of artificial intelligence (AI)-based technologies in medicine is advancing rapidly, but real-world clinical implementation has not yet become a reality. Here we review some of the key practical issues surrounding the implementation of AI into existing clinical workflows, including data sharing and privacy, transparency of algorithms, data standardization, and interoperability across multiple platforms, and concern for patient safety. We summarize the current regulatory environment in the United States and highlight comparisons with other regions in the world, notably Europe and China.},
  copyright = {2019 Springer Nature America, Inc.},
  langid = {english},
  keywords = {Data processing,Machine learning},
  file = {/Users/sovacool/Documents/Zotero/storage/B6N5J5NL/He et al_2019_The practical implementation of artificial intelligence technologies in medicine.pdf}
}

@article{janarthanan_clostridium_2012,
  title = {{\emph{Clostridium Difficile}}-{{Associated Diarrhea}} and {{Proton Pump Inhibitor Therapy}}: {{A Meta-Analysis}}},
  shorttitle = {Clostridium Difficile-{{Associated Diarrhea}} and {{Proton Pump Inhibitor Therapy}}},
  author = {Janarthanan, Sailajah and Ditah, Ivo and Adler, Douglas G. and Ehrinpreis, Murray N.},
  year = {2012},
  month = jul,
  journal = {Official journal of the American College of Gastroenterology | ACG},
  volume = {107},
  number = {7},
  pages = {1001},
  issn = {0002-9270},
  doi = {10.1038/ajg.2012.179},
  url = {https://journals.lww.com/ajg/Abstract/2012/07000/Clostridium_difficile_Associated_Diarrhea_and.10.aspx},
  urldate = {2023-06-05},
  abstract = {OBJECTIVES:~           Clostridium difficile-associated diarrhea (CDAD) is a major cause of morbidity and increasing health-care costs among hospitalized patients. Although exposure to antibiotics remains the most documented risk factor for CDAD, attention has recently been directed toward a plausible link with proton pump inhibitors (PPIs). However, the results of studies on the association between CDAD and PPIs remain controversial. We have conducted a meta-analysis to summarize the association between PPIs and CDAD among hospitalized patients.           METHODS:~           A systematic search of published literature on studies that investigated the association between PPIs and CDAD from 1990 to 2010 was conducted on Medline and PubMed. The identified articles were reviewed for additional references. The most adjusted risk estimates were extracted by two authors and summarized using random effects meta-analysis. We also conducted a subgroup analysis by study design. Publication bias was evaluated using the Begg and Egger tests. A sensitivity analysis using the Duval and Tweedie ``trim-and-fill'' method has also been performed.           RESULTS:~           Twenty-three studies including close to 300,000 patients met the inclusion criteria. There was a 65\% (summary risk estimate 1.69 with a 95\% confidence interval (CI) from 1.395 to 1.974;P{$<$}0.000) increase in the incidence of CDAD among patients on PPIs. By study design, whether case\textendash control study (17) or cohort study (6), there was still a significant increase in the incidence of CDAD among PPI users. The risk estimates were 2.31 (95\% CI from 1.72 to 3.10;P{$<$}0.001) and 1.48 (95\% CI from 1.25 to 1.75;P{$<$}0.001) for cohort and case\textendash control studies, respectively.           CONCLUSIONS:~           There is sufficient evidence to suggest that PPIs increase the incidence of CDAD. Our meta-analysis shows a 65\% increase in the incidence of CDAD among PPI users. We recommend that the routine use of PPIs for gastric ulcer prophylaxis should be more prudent. Establishing a guideline for the use of PPI may help in the future with the judicious use of PPIs. Further studies, preferably prospective, are needed to fully explore the association between PPIs and CDAD.},
  langid = {american},
  file = {/Users/sovacool/Documents/Zotero/storage/E4SYG7EF/Clostridium_difficile_Associated_Diarrhea_and.10.html}
}

@article{jiang_budget_2022,
  title = {Budget {{Impact Analysis}} of {{Fidaxomicin Versus Vancomycin}} for the {{Treatment}} of {{{\emph{Clostridioides}}}}{\emph{ Difficile}} {{Infection}} in the {{United States}}},
  author = {Jiang, Yiling and Sarpong, Eric M. and Sears, Pamela and Obi, Engels N.},
  year = {2022},
  month = feb,
  journal = {Infect Dis Ther},
  volume = {11},
  number = {1},
  pages = {111--126},
  issn = {2193-8229},
  doi = {10.1007/s40121-021-00480-0},
  url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8847493/},
  urldate = {2023-06-01},
  abstract = {Clostridioides difficile infection (CDI) is a common hospital-acquired infection that affects about half a million people in the US each year. In some patients who have already had CDI, it can recur. These recurrent infections can be difficult to treat, and they place a burden on the healthcare system. CDI is usually treated with the antibiotics fidaxomicin or vancomycin. Fidaxomicin is as effective as vancomycin for treating CDI but is even more effective than vancomycin at preventing CDI recurrence. However, fidaxomicin is more expensive. In this study, we estimated the impact of replacing vancomycin with fidaxomicin for treating CDI on the budget of a typical US hospital. We estimated that treating 15\% of patients with CDI using fidaxomicin in place of vancomycin would save the hospital between \$1105 and \$1150 in a year. This means that despite the higher cost of fidaxomicin, treating as few as 15\% of patients with CDI using fidaxomicin instead of vancomycin can be cost-saving for hospitals.},
  pmcid = {PMC8847493},
  pmid = {34292496},
  file = {/Users/sovacool/Documents/Zotero/storage/BJVEMAXC/Jiang et al_2022_Budget Impact Analysis of Fidaxomicin Versus Vancomycin for the Treatment of.pdf}
}

@article{johnson_clinical_2021,
  title = {Clinical {{Practice Guideline}} by the {{Infectious Diseases Society}} of {{America}} ({{IDSA}}) and {{Society}} for {{Healthcare Epidemiology}} of {{America}} ({{SHEA}}): 2021 {{Focused Update Guidelines}} on {{Management}} of {{{\emph{Clostridioides}}}}{\emph{ Difficile}} {{Infection}} in {{Adults}}},
  shorttitle = {Clinical {{Practice Guideline}} by the {{Infectious Diseases Society}} of {{America}} ({{IDSA}}) and {{Society}} for {{Healthcare Epidemiology}} of {{America}} ({{SHEA}})},
  author = {Johnson, Stuart and Lavergne, Val{\'e}ry and Skinner, Andrew M and {Gonzales-Luna}, Anne J and Garey, Kevin W and Kelly, Ciaran P and Wilcox, Mark H},
  year = {2021},
  month = sep,
  journal = {Clinical Infectious Diseases},
  volume = {73},
  number = {5},
  pages = {e1029-e1044},
  issn = {1058-4838, 1537-6591},
  doi = {10.1093/cid/ciab549},
  url = {https://academic.oup.com/cid/article/73/5/e1029/6298219},
  urldate = {2023-05-12},
  abstract = {Abstract             This clinical practice guideline is a focused update on management of Clostridioides difficile infection (CDI) in adults specifically addressing the use of fidaxomicin and bezlotoxumab for the treatment of CDI. This guideline was developed by a multidisciplinary panel representing the Infectious Diseases Society of America (IDSA) and the Society for Healthcare Epidemiology of America (SHEA). This guideline is intended for use by healthcare professionals who care for adults with CDI, including specialists in infectious diseases, gastroenterologists, hospitalists, pharmacists, and any clinicians and healthcare providers caring for these patients. The panel's recommendations for the management CDI are based upon evidence derived from topic-specific systematic literature reviews. Summarized below are the recommendations for the management of CDI in adults. The panel followed a systematic process which included a standardized methodology for rating the certainty of the evidence and strength of recommendation using the GRADE approach (Grading of Recommendations Assessment, Development, and Evaluation). A detailed description of background, methods, evidence summary and rationale that support each recommendation, and knowledge gaps can be found online in the full text.},
  langid = {english},
  file = {/Users/sovacool/Documents/Zotero/storage/E5BGL83X/Johnson et al. - 2021 - Clinical Practice Guideline by the Infectious Dise.pdf}
}

@article{kamran_early_2022,
  title = {Early Identification of Patients Admitted to Hospital for Covid-19 at Risk of Clinical Deterioration: Model Development and Multisite External Validation Study},
  shorttitle = {Early Identification of Patients Admitted to Hospital for Covid-19 at Risk of Clinical Deterioration},
  author = {Kamran, Fahad and Tang, Shengpu and Otles, Erkin and McEvoy, Dustin S. and Saleh, Sameh N. and Gong, Jen and Li, Benjamin Y. and Dutta, Sayon and Liu, Xinran and Medford, Richard J. and Valley, Thomas S. and West, Lauren R. and Singh, Karandeep and Blumberg, Seth and Donnelly, John P. and Shenoy, Erica S. and Ayanian, John Z. and Nallamothu, Brahmajee K. and Sjoding, Michael W. and Wiens, Jenna},
  year = {2022},
  month = feb,
  journal = {BMJ},
  volume = {376},
  pages = {e068576},
  publisher = {{British Medical Journal Publishing Group}},
  issn = {1756-1833},
  doi = {10.1136/bmj-2021-068576},
  url = {https://www.bmj.com/content/376/bmj-2021-068576},
  urldate = {2023-02-16},
  abstract = {Objective To create and validate a simple and transferable machine learning model from electronic health record data to accurately predict clinical deterioration in patients with covid-19 across institutions, through use of a novel paradigm for model development and code sharing. Design Retrospective cohort study. Setting One US hospital during 2015-21 was used for model training and internal validation. External validation was conducted on patients admitted to hospital with covid-19 at 12 other US medical centers during 2020-21. Participants 33 119 adults ({$\geq$}18 years) admitted to hospital with respiratory distress or covid-19. Main outcome measures An ensemble of linear models was trained on the development cohort to predict a composite outcome of clinical deterioration within the first five days of hospital admission, defined as in-hospital mortality or any of three treatments indicating severe illness: mechanical ventilation, heated high flow nasal cannula, or intravenous vasopressors. The model was based on nine clinical and personal characteristic variables selected from 2686 variables available in the electronic health record. Internal and external validation performance was measured using the area under the receiver operating characteristic curve (AUROC) and the expected calibration error\textemdash the difference between predicted risk and actual risk. Potential bed day savings were estimated by calculating how many bed days hospitals could save per patient if low risk patients identified by the model were discharged early. Results 9291 covid-19 related hospital admissions at 13 medical centers were used for model validation, of which 1510 (16.3\%) were related to the primary outcome. When the model was applied to the internal validation cohort, it achieved an AUROC of 0.80 (95\% confidence interval 0.77 to 0.84) and an expected calibration error of 0.01 (95\% confidence interval 0.00 to 0.02). Performance was consistent when validated in the 12 external medical centers (AUROC range 0.77-0.84), across subgroups of sex, age, race, and ethnicity (AUROC range 0.78-0.84), and across quarters (AUROC range 0.73-0.83). Using the model to triage low risk patients could potentially save up to 7.8 bed days per patient resulting from early discharge. Conclusion A model to predict clinical deterioration was developed rapidly in response to the covid-19 pandemic at a single hospital, was applied externally without the sharing of data, and performed well across multiple medical centers, patient subgroups, and time periods, showing its potential as a tool for use in optimizing healthcare resources.},
  chapter = {Research},
  copyright = {\textcopyright{} Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.. http://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.},
  langid = {english},
  pmid = {35177406},
  file = {/Users/sovacool/Documents/Zotero/storage/5MGXKI3J/Kamran et al_2022_Early identification of patients admitted to hospital for covid-19 at risk of.pdf}
}

@article{kassam_clostridium_2016,
  title = {{\emph{Clostridium Difficile}} Associated Risk of Death Score ({{CARDS}}): A Novel Severity Score to Predict Mortality among Hospitalised Patients with {{{\emph{C}}}}{\emph{. Difficile{$<$}i/{$>$} Infection}}},
  shorttitle = {Clostridium Difficile Associated Risk of Death Score ({{CARDS}})},
  author = {Kassam, Z. and Cribb Fabersunne, C. and Smith, M. B. and Alm, E. J. and Kaplan, G. G. and Nguyen, G. C. and Ananthakrishnan, A. N.},
  year = {2016},
  month = mar,
  journal = {Aliment Pharmacol Ther},
  volume = {43},
  number = {6},
  pages = {725--733},
  issn = {1365-2036},
  doi = {10.1111/apt.13546},
  abstract = {BACKGROUND: Clostridium difficile infection (CDI) is a public health threat and associated with significant mortality. However, there is a paucity of objectively derived CDI severity scoring systems to predict mortality. AIM: To develop a novel CDI risk score to predict mortality entitled: Clostridium difficile associated risk of death score (CARDS). METHODS: We obtained data from the United States 2011 Nationwide Inpatient Sample (NIS) database. All CDI-associated hospitalisations were identified using discharge codes (ICD-9-CM, 008.45). Multivariate logistic regression was utilised to identify independent predictors of mortality. Clostridium difficile associated risk of death score was calculated by assigning a numeric weight to each parameter based on their odds ratio in the final logistic model. Predictive properties of model discrimination were assessed using the c-statistic and validated in an independent sample using the 2010 NIS database. RESULTS: We identified 77 776 hospitalisations, yielding an estimate of 374 747 cases with an associated diagnosis of CDI in the US, 8\% of whom died in the hospital. The eight severity score predictors were identified on multivariate analysis: age, cardiopulmonary disease, malignancy, diabetes, inflammatory bowel disease, acute renal failure, liver disease and ICU admission, with weights ranging from -1 (for diabetes) to 5 (for ICU admission). The overall risk score in the cohort ranged from 0 to 18. Mortality increased significantly as CARDS increased. CDI-associated mortality was 1.2\% with a CARDS of 0 compared to 100\% with CARDS of 18. The model performed equally well in our validation cohort. CONCLUSION: Clostridium difficile associated risk of death score is a promising simple severity score to predict mortality among those hospitalised with C. difficile infection.},
  langid = {english},
  pmcid = {PMC5094350},
  pmid = {26849527},
  keywords = {Adolescent,Adult,Age Factors,Aged,{Aged, 80 and over},Clostridioides difficile,Clostridium Infections,Comorbidity,Female,Health Status Indicators,Hospitalization,Humans,Inpatients,Logistic Models,Male,Middle Aged,Multivariate Analysis,Odds Ratio,Socioeconomic Factors,United States,Young Adult},
  file = {/Users/sovacool/Documents/Zotero/storage/TZQTWNQE/Kassam et al_2016_Clostridium difficile associated risk of death score (CARDS).pdf}
}

@article{keller_treatment_2015,
  title = {Treatment of {{Recurrent}} and {{Severe Clostridium Difficile Infection}}},
  author = {Keller, J.J. and Kuijper, E.J.},
  year = {2015},
  journal = {Annual Review of Medicine},
  volume = {66},
  number = {1},
  pages = {373--386},
  doi = {10.1146/annurev-med-070813-114317},
  url = {https://doi.org/10.1146/annurev-med-070813-114317},
  urldate = {2023-06-04},
  abstract = {Clostridium difficile infection (CDI) is a serious complication of hospitalization and antibiotic use with a high mortality and very high costs. Despite appropriate treatment, a subset of patients develop chronic recurrent CDI. Some other patients develop severe and life-threatening colitis. The risk factors, pathogenesis, and treatment of recurrent CDI and severe CDI are discussed in this review. In particular, fecal microbiota transplantation (FMT) as a treatment strategy is outlined and a treatment algorithm incorporating FMT is described.},
  pmid = {25587656},
  keywords = {donor feces,fidaxomicin,microbiota,transplantation},
  file = {/Users/sovacool/Documents/Zotero/storage/ALXGV36D/Keller_Kuijper_2015_Treatment of Recurrent and Severe Clostridium Difficile Infection.pdf}
}

@article{kelly_can_2012,
  title = {Can We Identify Patients at High Risk of Recurrent {{{\emph{Clostridium}}}}{\emph{ Difficile}} Infection?},
  author = {Kelly, C. P.},
  year = {2012},
  month = jan,
  journal = {Clinical Microbiology and Infection},
  volume = {18},
  pages = {21--27},
  publisher = {{Elsevier}},
  issn = {1198-743X},
  doi = {10.1111/1469-0691.12046},
  url = {https://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(14)60844-2/fulltext},
  urldate = {2023-06-04},
  langid = {english},
  pmid = {23121551},
  keywords = {Antibiotic-associated diarrhoea,C. difficile,clinical prediction rule,colitis,recurrent C. difficile infection},
  file = {/Users/sovacool/Documents/Zotero/storage/WAEXJPBY/Kelly_2012_Can we identify patients at high risk of recurrent Clostridium difficile.pdf}
}

@article{kim_how_2021,
  title = {How {{Does Cost-Effectiveness Analysis Inform Health Care Decisions}}?},
  author = {Kim, David D. and Basu, Anirban},
  year = {2021},
  month = aug,
  journal = {AMA Journal of Ethics},
  volume = {23},
  number = {8},
  pages = {639--647},
  publisher = {{American Medical Association}},
  issn = {2376-6980},
  doi = {10.1001/amajethics.2021.639},
  url = {https://journalofethics.ama-assn.org/article/how-does-cost-effectiveness-analysis-inform-health-care-decisions/2021-08},
  urldate = {2023-04-12},
  abstract = {Cost-effectiveness analysis (CEA) provides a formal assessment of trade-offs involving benefits},
  file = {/Users/sovacool/Documents/Zotero/storage/CD8C3NAV/Kim_Basu_2021_How Does Cost-Effectiveness Analysis Inform Health Care Decisions.pdf}
}

@article{kim_recurrent_2019,
  title = {Recurrent {{Clostridium}} Difficile {{Infection}}: {{Risk Factors}}, {{Treatment}}, and {{Prevention}}},
  shorttitle = {Recurrent {{Clostridium}} Difficile {{Infection}}},
  author = {Kim, Jung Hoon Song {and} You Sun},
  year = {2019},
  month = jan,
  journal = {Gut and Liver},
  volume = {13},
  number = {1},
  pages = {16--24},
  publisher = {{Editorial Office of Gut and Liver}},
  doi = {10.5009/gnl18071},
  url = {https://www.gutnliver.org/journal/view.html?doi=10.5009/gnl18071},
  urldate = {2021-12-14},
  abstract = {Jung Hoon Song and You Sun Kim. Gut and Liver 2019;13:16-24. https://doi.org/10.5009/gnl18071},
  langid = {english},
  file = {/Users/sovacool/Library/CloudStorage/GoogleDrive-sovacool@umich.edu/Shared drives/umich-shared/Zotero/Kim_2019_Gut_and_Liver.pdf}
}

@article{kociolek_breakthroughs_2016,
  title = {Breakthroughs in the Treatment and Prevention of {{Clostridium}} Difficile Infection},
  author = {Kociolek, Larry K. and Gerding, Dale N.},
  year = {2016},
  month = mar,
  journal = {Nat Rev Gastroenterol Hepatol},
  volume = {13},
  number = {3},
  pages = {150--160},
  publisher = {{Nature Publishing Group}},
  issn = {1759-5053},
  doi = {10.1038/nrgastro.2015.220},
  url = {https://www.nature.com/articles/nrgastro.2015.220},
  urldate = {2021-08-27},
  abstract = {The most commonly prescribed antibiotic therapies for Clostridium difficile infections (CDIs), namely metronidazole and vancomycin, have a broad antibiotic spectrum and are associated with unacceptably high CDI recurrence ratesEmerging CDI therapies limit further perturbation of and/or restore the gut microbiota to its pre-morbid state, reduce colonization by toxigenic strains and bolster the host immune response against C. difficile toxinsAs emerging narrow-spectrum CDI antibiotic therapies have limited activity against several species of enteric commensal bacteria, these new antibiotics might result in less frequent CDI recurrencesFaecal microbiota transplantation is highly efficacious for preventing CDI recurrences, but questions regarding the optimal route of administration and long-term risks remainOral administration of spores from nontoxigenic C. difficile strains could prevent CDI by preventing intestinal colonization with toxigenic strains of C. difficileEmerging immunological therapies, including monoclonal antibodies and vaccines against C. difficile toxins, might protect against symptomatic CDI and subsequent CDI recurrences},
  copyright = {2016 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.},
  langid = {english},
  annotation = {Bandiera\_abtest: a Cg\_type: Nature Research Journals Primary\_atype: Reviews Subject\_term: Antibiotics;Clostridium difficile;Microbiota;Vaccines Subject\_term\_id: antibiotics;clostridium-difficile;microbiota;vaccines},
  file = {/Users/sovacool/Library/CloudStorage/GoogleDrive-sovacool@umich.edu/Shared drives/umich-shared/Zotero/Kociolek_et_al_2016_Nat_Rev_Gastroenterol_Hepatol.pdf}
}

@article{koster_snakemake_2012,
  title = {Snakemake \textemdash{} a Scalable Bioinformatics Workflow Engine},
  author = {K{\"o}ster, Johannes and Rahmann, Sven},
  year = {2012},
  month = oct,
  journal = {Bioinformatics},
  volume = {28},
  number = {19},
  pages = {2520--2522},
  publisher = {{Oxford Academic}},
  issn = {1367-4803},
  doi = {10.1093/bioinformatics/bts480},
  abstract = {Abstract. Summary: Snakemake is a workflow engine that provides a readable Python-based workflow definition language and a powerful execution environment that},
  langid = {english},
  file = {/Users/sovacool/Documents/Zotero/storage/UA6VMRD7/bioinformatics_28_19_2520.pdf}
}

@article{kozich_development_2013,
  title = {Development of a {{Dual-Index Sequencing Strategy}} and {{Curation Pipeline}} for {{Analyzing Amplicon Sequence Data}} on the {{MiSeq Illumina Sequencing Platform}}},
  author = {Kozich, James J. and Westcott, Sarah L. and Baxter, Nielson T. and Highlander, Sarah K. and Schloss, Patrick D.},
  year = {2013},
  month = sep,
  journal = {Appl. Environ. Microbiol.},
  volume = {79},
  number = {17},
  pages = {5112--5120},
  issn = {0099-2240, 1098-5336},
  doi = {10.1128/AEM.01043-13},
  url = {http://aem.asm.org/lookup/doi/10.1128/AEM.01043-13},
  urldate = {2019-05-16},
  abstract = {ABSTRACT             Rapid advances in sequencing technology have changed the experimental landscape of microbial ecology. In the last 10 years, the field has moved from sequencing hundreds of 16S rRNA gene fragments per study using clone libraries to the sequencing of millions of fragments per study using next-generation sequencing technologies from 454 and Illumina. As these technologies advance, it is critical to assess the strengths, weaknesses, and overall suitability of these platforms for the interrogation of microbial communities. Here, we present an improved method for sequencing variable regions within the 16S rRNA gene using Illumina's MiSeq platform, which is currently capable of producing paired 250-nucleotide reads. We evaluated three overlapping regions of the 16S rRNA gene that vary in length (i.e., V34, V4, and V45) by resequencing a mock community and natural samples from human feces, mouse feces, and soil. By titrating the concentration of 16S rRNA gene amplicons applied to the flow cell and using a quality score-based approach to correct discrepancies between reads used to construct contigs, we were able to reduce error rates by as much as two orders of magnitude. Finally, we reprocessed samples from a previous study to demonstrate that large numbers of samples could be multiplexed and sequenced in parallel with shotgun metagenomes. These analyses demonstrate that our approach can provide data that are at least as good as that generated by the 454 platform while providing considerably higher sequencing coverage for a fraction of the cost.},
  langid = {english},
  keywords = {Schloss\_Lab,Schloss\textsubscript{L}ab},
  file = {/Users/sovacool/Library/CloudStorage/GoogleDrive-sovacool@umich.edu/Shared drives/umich-shared/Zotero/Kozich_et_al_2013_Appl._Environ._Microbiol..pdf}
}

@article{kwon_morbidity_2015,
  title = {The Morbidity, Mortality, and Costs Associated with {{{\emph{Clostridium}}}}{\emph{ Difficile}} Infection},
  author = {Kwon, Jennie H. and Olsen, Margaret A. and Dubberke, Erik R.},
  year = {2015},
  month = mar,
  journal = {Infect Dis Clin North Am},
  volume = {29},
  number = {1},
  pages = {123--134},
  issn = {1557-9824},
  doi = {10.1016/j.idc.2014.11.003},
  abstract = {Clostridium difficile infection (CDI) is the most common cause of infectious health care-associated diarrhea and is a major burden to patients and the health care system. The incidence and severity of CDI remain at historically high levels. This article reviews the morbidity, mortality, and costs associated with CDI.},
  langid = {english},
  pmid = {25677706},
  keywords = {Acute Disease,Anti-Bacterial Agents,Clostridioides difficile,Clostridium difficile,Clostridium Infections,Costs,Cross Infection,Disease Outbreaks,Hospital Costs,Humans,Intestinal Diseases,Morbidity,Mortality,Risk Factors}
}

@article{laupacis_assessment_1988,
  title = {An Assessment of Clinically Useful Measures of the Consequences of Treatment},
  author = {Laupacis, Andreas and Sackett, David L. and Roberts, Robin S.},
  year = {1988},
  journal = {New England Journal of Medicine},
  volume = {318},
  number = {26},
  eprint = {https://doi.org/10.1056/NEJM198806303182605},
  pages = {1728--1733},
  doi = {10.1056/NEJM198806303182605},
  url = {https://doi.org/10.1056/NEJM198806303182605},
  file = {/Users/sovacool/Documents/Zotero/storage/U8QFNNJX/nejm198806303182605.pdf}
}

@article{lesniak_gut_2022,
  title = {The {{Gut Bacterial Community Potentiates}} {{{\emph{Clostridioides}}}}{\emph{ Difficile}} {{Infection Severity}}},
  author = {Lesniak, Nicholas A. and Schubert, Alyxandria M. and Flynn, Kaitlin J. and Leslie, Jhansi L. and Sinani, Hamide and Bergin, Ingrid L. and Young, Vincent B. and Schloss, Patrick D.},
  year = {2022},
  month = jul,
  journal = {mBio},
  volume = {13},
  number = {4},
  pages = {e01183-22},
  publisher = {{American Society for Microbiology}},
  doi = {10.1128/mbio.01183-22},
  url = {https://journals.asm.org/doi/10.1128/mbio.01183-22},
  urldate = {2023-02-03},
  abstract = {The severity of Clostridioides difficile infections (CDI) has increased over the last few decades. Patient age, white blood cell count, and creatinine levels as well as C. difficile ribotype and toxin genes have been associated with disease severity. However, it is unclear whether specific members of the gut microbiota are associated with variations in disease severity. The gut microbiota is known to interact with C. difficile during infection. Perturbations to the gut microbiota are necessary for C. difficile to colonize the gut. The gut microbiota can inhibit C. difficile colonization through bile acid metabolism, nutrient consumption, and bacteriocin production. Here, we sought to demonstrate that members of the gut bacterial communities can also contribute to disease severity. We derived diverse gut communities by colonizing germfree mice with different human fecal communities. The mice were then infected with a single C. difficile ribotype 027 clinical isolate, which resulted in moribundity and histopathologic differences. The variation in severity was associated with the human fecal community that the mice received. Generally, bacterial populations with pathogenic potential, such as Enterococcus, Helicobacter, and Klebsiella, were associated with more-severe outcomes. Bacterial groups associated with fiber degradation and bile acid metabolism, such as Anaerotignum, Blautia, Lactonifactor, and Monoglobus, were associated with less-severe outcomes. These data indicate that, in addition to the host and C. difficile subtype, populations of gut bacteria can influence CDI disease severity. IMPORTANCE Clostridioides difficile colonization can be asymptomatic or develop into an infection ranging in severity from mild diarrhea to toxic megacolon, sepsis, and death. Models that predict severity and guide treatment decisions are based on clinical factors and C. difficile characteristics. Although the gut microbiome plays a role in protecting against CDI, its effect on CDI disease severity is unclear and has not been incorporated into disease severity models. We demonstrated that variation in the microbiome of mice colonized with human feces yielded a range of disease outcomes. These results revealed groups of bacteria associated with both severe and mild C. difficile infection outcomes. Gut bacterial community data from patients with CDI could improve our ability to identify patients at risk of developing more severe disease and improve interventions that target C. difficile and the gut bacteria to reduce host damage.},
  file = {/Users/sovacool/Documents/Zotero/storage/WW4S4DDK/Lesniak et al_2022_The Gut Bacterial Community Potentiates Clostridioides difficile Infection.pdf}
}

@article{li_using_2019,
  title = {Using {{Machine Learning}} and the {{Electronic Health Record}} to {{Predict Complicated}} {{{\emph{Clostridium}}}}{\emph{ Difficile}} {{Infection}}},
  author = {Li, Benjamin Y. and Oh, Jeeheh and Young, Vincent B. and Rao, Krishna and Wiens, Jenna},
  year = {2019},
  month = may,
  journal = {Open Forum Infect Dis},
  volume = {6},
  number = {5},
  pages = {ofz186},
  issn = {2328-8957},
  doi = {10.1093/ofid/ofz186},
  abstract = {Background: Clostridium (Clostridioides) difficile infection (CDI) is a health care-associated infection that can lead to serious complications. Potential complications include intensive care unit (ICU) admission, development of toxic megacolon, need for colectomy, and death. However, identifying the patients most likely to develop complicated CDI is challenging. To this end, we explored the utility of a machine learning (ML) approach for patient risk stratification for complications using electronic health record (EHR) data. Methods: We considered adult patients diagnosed with CDI between October 2010 and January 2013 at the University of Michigan hospitals. Cases were labeled complicated if the infection resulted in ICU admission, colectomy, or 30-day mortality. Leveraging EHR data, we trained a model to predict subsequent complications on each of the 3 days after diagnosis. We compared our EHR-based model to one based on a small set of manually curated features. We evaluated model performance using a held-out data set in terms of the area under the receiver operating characteristic curve (AUROC). Results: Of 1118 cases of CDI, 8\% became complicated. On the day of diagnosis, the model achieved an AUROC of 0.69 (95\% confidence interval [CI], 0.55-0.83). Using data extracted 2 days after CDI diagnosis, performance increased (AUROC, 0.90; 95\% CI, 0.83-0.95), outperforming a model based on a curated set of features (AUROC, 0.84; 95\% CI, 0.75-0.91). Conclusions: Using EHR data, we can accurately stratify CDI cases according to their risk of developing complications. Such an approach could be used to guide future clinical studies investigating interventions that could prevent or mitigate complicated CDI.},
  langid = {english},
  pmcid = {PMC6527086},
  pmid = {31139672},
  keywords = {Clostridium (Clostridioides) difficile infection,complications,electronic health records,machine learning,patient risk stratification},
  file = {/Users/sovacool/Documents/Zotero/storage/Q75LA2UC/ofz186_suppl_supplementary_materials.docx;/Users/sovacool/Documents/Zotero/storage/V5XLHW6E/ofz186_suppl_supplementary_materials.pdf;/Users/sovacool/Library/CloudStorage/GoogleDrive-sovacool@umich.edu/Shared drives/umich-shared/Zotero/Li_et_al_2019_Open_Forum_Infect_Dis.pdf}
}

@article{liu_no_2020,
  title = {`{{No}} Growth to Date'? {{Predicting}} Positive Blood Cultures in Critical Illness},
  shorttitle = {`{{No}} Growth to Date'?},
  author = {Liu, Vincent X. and Wiens, Jenna},
  year = {2020},
  month = mar,
  journal = {Intensive Care Med},
  volume = {46},
  number = {3},
  pages = {525--527},
  issn = {1432-1238},
  doi = {10.1007/s00134-019-05917-2},
  url = {https://doi.org/10.1007/s00134-019-05917-2},
  urldate = {2023-05-10},
  langid = {english},
  file = {/Users/sovacool/Documents/Zotero/storage/T25ZNBV6/Liu_Wiens_2020_No growth to date.pdf}
}

@article{liu_number_2019,
  title = {The Number Needed to Benefit: Estimating the Value of Predictive Analytics in Healthcare},
  shorttitle = {The Number Needed to Benefit},
  author = {Liu, Vincent X and Bates, David W and Wiens, Jenna and Shah, Nigam H},
  year = {2019},
  month = dec,
  journal = {Journal of the American Medical Informatics Association},
  volume = {26},
  number = {12},
  pages = {1655--1659},
  issn = {1527-974X},
  doi = {10.1093/jamia/ocz088},
  url = {https://doi.org/10.1093/jamia/ocz088},
  urldate = {2022-06-28},
  abstract = {Predictive analytics in health care has generated increasing enthusiasm recently, as reflected in a rapidly growing body of predictive models reported in literature and in real-time embedded models using electronic health record data. However, estimating the benefit of applying any single model to a specific clinical problem remains challenging today. Developing a shared framework for estimating model value is therefore critical to facilitate the effective, safe, and sustainable use of predictive tools into the future. We highlight key concepts within the prediction-action dyad that together are expected to impact model benefit. These include factors relevant to model prediction (including the number needed to screen) as well as those relevant to the subsequent action (number needed to treat). In the simplest terms, a number needed to benefit contextualizes the numbers needed to screen and treat, offering an opportunity to estimate the value of a clinical predictive model in action.},
  file = {/Users/sovacool/Documents/Zotero/storage/96GXUWTX/Liu et al_2019_The number needed to benefit.pdf;/Users/sovacool/Library/CloudStorage/GoogleDrive-sovacool@umich.edu/Shared drives/umich-shared/Zotero/Liu_et_al_2019_Journal_of_the_American_Medical_Informatics_Association.pdf;/Users/sovacool/Documents/Zotero/storage/72PMC64R/5516459.html}
}

@article{long_oral_2022,
  title = {Oral Fidaxomicin versus Vancomycin for {{{\emph{Clostridioides}}}}{\emph{ Difficile}} Infection},
  author = {Long, Brit and Gottlieb, Michael},
  year = {2022},
  journal = {Academic Emergency Medicine},
  volume = {29},
  number = {12},
  pages = {1506--1507},
  issn = {1553-2712},
  doi = {10.1111/acem.14600},
  url = {https://onlinelibrary.wiley.com/doi/abs/10.1111/acem.14600},
  urldate = {2023-05-29},
  langid = {english},
  keywords = {Clostridioides difficile,Clostridioides difficile infection,diarrhea,gastroenterology,infectious diseases},
  file = {/Users/sovacool/Documents/Zotero/storage/IMEJF4FT/Long_Gottlieb_2022_Oral fidaxomicin versus vancomycin for Clostridioides difficile infection.pdf;/Users/sovacool/Documents/Zotero/storage/HWARLTF6/acem.html}
}

@article{louie_fidaxomicin_2011,
  title = {Fidaxomicin versus {{Vancomycin}} for {{Clostridium}} Difficile {{Infection}}},
  author = {Louie, Thomas J. and Miller, Mark A. and Mullane, Kathleen M. and Weiss, Karl and Lentnek, Arnold and Golan, Yoav and Gorbach, Sherwood and Sears, Pamela and Shue, Youe-Kong},
  year = {2011},
  month = feb,
  journal = {New England Journal of Medicine},
  volume = {364},
  number = {5},
  pages = {422--431},
  publisher = {{Massachusetts Medical Society}},
  issn = {0028-4793},
  doi = {10.1056/NEJMoa0910812},
  url = {https://doi.org/10.1056/NEJMoa0910812},
  urldate = {2023-04-14},
  abstract = {Clostridium difficile infection generally occurs after exposure to broad-spectrum antibiotics. The incidence and severity of C. difficile infection are increasing. The increases have been ascribed to the emergence of a hypervirulent C. difficile strain, known variously as North American Pulsed Field type 1 (NAP1), restriction-endonuclease analysis (REA) type BI, or polymerase-chain-reaction ribotype 027 (referred to collectively as the NAP1/BI/027 strain).1\textendash 4 Furthermore, the rates of death associated with C. difficile infection are rising,5\textendash 7 and the infection is occurring in populations that were previously considered to be at low risk, such as young, healthy persons living in the community and . . .},
  pmid = {21288078},
  file = {/Users/sovacool/Documents/Zotero/storage/A9JWEYN8/Louie et al_2011_Fidaxomicin versus Vancomycin for Clostridium difficile Infection.pdf}
}

@article{lucado_clostridium_2012,
  title = {{\emph{Clostridium Difficile}} {{Infections}} ({{CDI}}) in {{Hospital Stays}}, 2009. {{HCUP Statistical Brief}} \#124},
  author = {Lucado, Jennifer and Elixhauser, Anne},
  year = {2012},
  journal = {AHRQ},
  url = {http://www.hcup-us.ahrq.gov/reports/statbriefs/sb124.pdf},
  langid = {english},
  file = {/Users/sovacool/Documents/Zotero/storage/SEJXD88S/Lucado and Elixhauser - Clostridium difficile Infections (CDI) in Hospital.pdf}
}

@article{magill_multistate_2014,
  title = {Multistate {{Point-Prevalence Survey}} of {{Health Care}}\textendash{{Associated Infections}}},
  author = {Magill, Shelley S. and Edwards, Jonathan R. and Bamberg, Wendy and Beldavs, Zintars G. and Dumyati, Ghinwa and Kainer, Marion A. and Lynfield, Ruth and Maloney, Meghan and {McAllister-Hollod}, Laura and Nadle, Joelle and Ray, Susan M. and Thompson, Deborah L. and Wilson, Lucy E. and Fridkin, Scott K.},
  year = {2014},
  month = mar,
  journal = {N Engl J Med},
  volume = {370},
  number = {13},
  pages = {1198--1208},
  publisher = {{Massachusetts Medical Society}},
  issn = {0028-4793},
  doi = {10.1056/NEJMoa1306801},
  url = {https://www.nejm.org/doi/10.1056/NEJMoa1306801},
  urldate = {2023-06-04},
  file = {/Users/sovacool/Documents/Zotero/storage/7YTFKUL4/Magill et al_2014_Multistate Point-Prevalence Survey of Health CareAssociated Infections.pdf}
}

@article{mamoon_fecal_2020,
  title = {Fecal {{Microbiota Transplants Annually}} and {{Their Positive Clinical Impact}}},
  author = {Mamoon, Lamia and Olesen, Scott W.},
  year = {2020},
  month = nov,
  journal = {Clinical and Translational Gastroenterology},
  volume = {11},
  number = {11},
  pages = {e00247},
  issn = {2155-384X},
  doi = {10.14309/ctg.0000000000000247},
  url = {https://journals.lww.com/ctg/Fulltext/2020/11000/Fecal_Microbiota_Transplants_Annually_and_Their.4.aspx},
  urldate = {2023-05-08},
  abstract = {INTRODUCTION:~           Although fecal microbiota transplantation (FMT) is a recommended, clinically efficacious, and cost-effective treatment for recurrent Clostridioides difficile infection (CDI), the scale of FMT use in the United States is unknown.           METHODS:~           We developed a population-level CDI model.           RESULTS:~           We estimated that 48,000 FMTs could be performed annually, preventing 32,000 CDI recurrences.           DISCUSSION:~           Improving access to FMT could lead to tens of thousands fewer C. difficile episodes per year.},
  langid = {american},
  file = {/Users/sovacool/Documents/Zotero/storage/Q7D53SXQ/Mamoon_Olesen_2020_Fecal Microbiota Transplants Annually and Their Positive Clinical Impact.pdf;/Users/sovacool/Documents/Zotero/storage/LS69AGYP/Fecal_Microbiota_Transplants_Annually_and_Their.4.html}
}

@article{mcdonald_clinical_2018,
  title = {Clinical {{Practice Guidelines}} for {{{\emph{Clostridium}}}}{\emph{ Difficile}} {{Infection}} in {{Adults}} and {{Children}}: 2017 {{Update}} by the {{Infectious Diseases Society}} of {{America}} ({{IDSA}}) and {{Society}} for {{Healthcare Epidemiology}} of {{America}} ({{SHEA}})},
  shorttitle = {Clinical {{Practice Guidelines}} for {{Clostridium}} Difficile {{Infection}} in {{Adults}} and {{Children}}},
  author = {McDonald, L Clifford and Gerding, Dale N and Johnson, Stuart and Bakken, Johan S and Carroll, Karen C and Coffin, Susan E and Dubberke, Erik R and Garey, Kevin W and Gould, Carolyn V and Kelly, Ciaran and Loo, Vivian and Shaklee Sammons, Julia and Sandora, Thomas J and Wilcox, Mark H},
  year = {2018},
  month = mar,
  journal = {Clinical Infectious Diseases},
  volume = {66},
  number = {7},
  pages = {e1-e48},
  issn = {1058-4838, 1537-6591},
  doi = {10.1093/cid/cix1085},
  url = {https://academic.oup.com/cid/article/66/7/e1/4855916},
  urldate = {2023-05-18},
  abstract = {Abstract             A panel of experts was convened by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) to update the 2010 clinical practice guideline on Clostridium difficile infection (CDI) in adults. The update, which has incorporated recommendations for children (following the adult recommendations for epidemiology, diagnosis, and treatment), includes significant changes in the management of this infection and reflects the evolving controversy over best methods for diagnosis. Clostridium difficile remains the most important cause of healthcare-associated diarrhea and has become the most commonly identified cause of healthcare-associated infection in adults in the United States. Moreover, C. difficile has established itself as an important community pathogen. Although the prevalence of the epidemic and virulent ribotype 027 strain has declined markedly along with overall CDI rates in parts of Europe, it remains one of the most commonly identified strains in the United States where it causes a sizable minority of CDIs, especially healthcare-associated CDIs. This guideline updates recommendations regarding epidemiology, diagnosis, treatment, infection prevention, and environmental management.},
  langid = {english},
  file = {/Users/sovacool/Documents/Zotero/storage/AI46VG5H/McDonald et al. - 2018 - Clinical Practice Guidelines for Clostridium diffi.pdf}
}

@article{mcdonald_recommendations_2007,
  title = {Recommendations for Surveillance of {{{\emph{Clostridium}}}}{\emph{ Difficile}}\textendash{{Associated}} Disease},
  author = {McDonald, L. Clifford and Coignard, Bruno and Dubberke, Erik and Song, Xiaoyan and Horan, Teresa and Kutty, Preeta K.},
  year = {2007},
  journal = {Infection Control \&amp; Hospital Epidemiology},
  volume = {28},
  number = {2},
  pages = {140--145},
  publisher = {{Cambridge University Press}},
  doi = {10.1086/511798}
}

@misc{michigan_medicine_clostridioides_nodate,
  title = {Clostridioides Difficile {{Infection}} in {{Adults}} and {{Children}}},
  author = {Michigan Medicine},
  url = {https://www.med.umich.edu/1info/FHP/practiceguides/InptCDiff/C-Diff.pdf},
  urldate = {2023-05-12},
  file = {/Users/sovacool/Documents/Zotero/storage/W482V2ZA/C-Diff.pdf}
}

@misc{michigan_medicine_guidelines_nodate,
  title = {{{GUIDELINES FOR TREATMENT OF CLOSTRIDIOIDES DIFFICILE COLITIS IN ADULTS}}},
  author = {Michigan Medicine},
  url = {https://www.med.umich.edu/asp/pdf/adult_guidelines/Cdiff_ADULT.pdf},
  urldate = {2023-05-12},
  file = {/Users/sovacool/Documents/Zotero/storage/5U8E8TR5/Cdiff_ADULT.pdf}
}

@article{mileto_bezlotoxumab_2022,
  title = {Bezlotoxumab Prevents Extraintestinal Organ Damage Induced by {{Clostridioides}} Difficile Infection},
  author = {Mileto, Steven J. and Hutton, Melanie L. and Walton, Sarah L. and Das, Antariksh and Ioannidis, Lisa J. and Ketagoda, Don and Quinn, Kylie M. and Denton, Kate M. and Hansen, Diana S. and Lyras, Dena},
  year = {2022},
  month = dec,
  journal = {Gut Microbes},
  volume = {14},
  number = {1},
  pages = {2117504},
  publisher = {{Taylor \& Francis}},
  issn = {1949-0976},
  doi = {10.1080/19490976.2022.2117504},
  url = {https://doi.org/10.1080/19490976.2022.2117504},
  urldate = {2023-05-09},
  abstract = {Clostridioides difficile is the most common cause of infectious antibiotic-associated diarrhea, with disease mediated by two major toxins TcdA and TcdB. In severe cases, systemic disease complications may arise, resulting in fatal disease. Systemic disease in animal models has been described, with thymic damage an observable consequence of severe disease in mice. Using a mouse model of C. difficile infection, we examined this disease phenotype, focussing on the thymus and serum markers of systemic disease. The efficacy of bezlotoxumab, a monoclonal TcdB therapeutic, to prevent toxin mediated systemic disease complications was also examined. C. difficile infection causes toxin-dependent thymic damage and CD4+CD8+ thymocyte depletion in mice. These systemic complications coincide with changes in biochemical markers of liver and kidney function, including increased serum urea and creatinine, and hypoglycemia. Administration of bezlotoxumab during C. difficile infection prevents systemic disease and thymic atrophy, without blocking gut damage, suggesting the leakage of gut contents into circulation may influence systemic disease. As the thymus has such a crucial role in T cell production and immune system development, these findings may have important implications in relapse of C. difficile disease and impaired immunity during C. difficile infection. The prevention of thymic atrophy and reduced systemic response following bezlotoxumab treatment, without altering colonic damage, highlights the importance of systemic disease in C. difficile infection, and provides new insights into the mechanism of action for this therapeutic.Abbreviations: Acute kidney injury (AKI); Alanine Transaminase (ALT); Aspartate Aminotransferase (AST); C. difficile infection (CDI); chronic kidney disease (CKD); combined repetitive oligo-peptides (CROPS); cardiovascular disease (CVD); Double positive (DP); hematoxylin and eosin (H\&E); immunohistochemical (IHC); multiple organ dysfunction syndrome (MODS); phosphate buffered saline (PBS); standard error of the mean (SEM); surface layer proteins (SLP); Single positive (SP); wild-type (WT).},
  pmid = {36045589},
  keywords = {bacterial infection,Clostridioides difficile,colon damage,epithelial damage,leaky gut,systemic disease,toxin},
  file = {/Users/sovacool/Documents/Zotero/storage/XHADNI88/Mileto et al_2022_Bezlotoxumab prevents extraintestinal organ damage induced by Clostridioides.pdf}
}

@article{napolitano_clostridium_2017,
  title = {{\emph{Clostridium Difficile}} Disease: {{Diagnosis}}, Pathogenesis, and Treatment Update},
  shorttitle = {Clostridium Difficile Disease},
  author = {Napolitano, Lena M. and Edmiston, Charles E.},
  year = {2017},
  month = aug,
  journal = {Surgery},
  volume = {162},
  number = {2},
  pages = {325--348},
  issn = {0039-6060},
  doi = {10.1016/j.surg.2017.01.018},
  url = {https://www.sciencedirect.com/science/article/pii/S003960601730079X},
  urldate = {2023-06-04},
  abstract = {Clostridium difficile infections are the leading cause of health care\textendash associated infectious diarrhea, posing a significant risk for both medical and surgical patients. Because of the significant morbidity and mortality associated with C difficile infections, knowledge of the epidemiology of C difficile in combination with a high index of suspicion and susceptible patient populations (including surgical, postcolectomy, and inflammatory bowel disease patients) is warranted. C difficile infections present with a wide spectrum of disease, ranging from mild diarrhea to fulminant colitis or small bowel enteritis and recurrent C difficile infections. Early implementation of medical and operative treatment strategies for C difficile infections is imperative for optimal patient outcomes. National and international guidelines recommend early operative consultation and total abdominal colectomy with end ileostomy and preservation of rectum. Diverting loop ileostomy and colonic lavage followed by intravenous metronidazole and intracolonic vancomycin administered via the efferent limb of the ileostomy should be considered as an alternative to total colectomy in selected patients. New and emerging strategies for C difficile infection treatment include monoclonal antibodies, vaccines, probiotics, biotherapeutics, and new antibiotics. A successful C difficile prevention and eradication program requires a multidisciplinary approach that includes early disease recognition, implementation of guidelines for monitoring adherence to environmental control, judicious hand hygiene, evidence-based treatment and management strategies, and a focused antibiotic stewardship program. Surgeons are an important part of the clinical team in the management of C difficile infection prevention and treatment.},
  langid = {english},
  file = {/Users/sovacool/Documents/Zotero/storage/L9GYEBSM/Napolitano_Edmiston_2017_Clostridium difficile disease.pdf;/Users/sovacool/Documents/Zotero/storage/HUENGP9V/S003960601730079X.html}
}

@article{nuovo_reporting_2002,
  title = {Reporting {{Number Needed}} to {{Treat}} and {{Absolute Risk Reduction}} in {{Randomized Controlled Trials}}},
  author = {Nuovo, Jim and Melnikow, Joy and Chang, Denise},
  year = {2002},
  month = jun,
  journal = {JAMA},
  volume = {287},
  number = {21},
  pages = {2813--2814},
  issn = {0098-7484},
  doi = {10.1001/jama.287.21.2813},
  url = {https://doi.org/10.1001/jama.287.21.2813},
  urldate = {2023-06-01},
  abstract = {ContextOngoing efforts to improve the quality of reporting for randomized controlled trials (RCTs) include the Consolidated Standards of Reporting Trials (CONSORT) statement. We examined the frequency of explicit reporting of the number needed to treat (NNT) and the absolute risk reduction (ARR) in RCTs.MethodsFive frequently cited journals were investigated: Annals of Internal Medicine, BMJ, JAMA, The Lancet, and the New England Journal of Medicine. For each journal, 4 years were evaluated: 1989, 1992, 1995, and 1998. All issues of each journal for each year were reviewed manually. Eligible articles were those in which an RCT was conducted on the use of a medication showing a significant treatment effect. Elements abstracted from each eligible article were the condition investigated, event being treated or prevented, intervention, study results, and reporting methods (relative risk reduction, NNT, and ARR).ResultsOf 359 eligible articles, NNT was reported in 8 articles. Six of the 8 studies were from 1998. Absolute risk reduction was reported in 18 articles, 10 of which were from 1998.ConclusionsDespite CONSORT recommendations, few authors expressed their findings in terms of NNT or ARR. Consideration should be given to including these values in reports of RCTs.},
  file = {/Users/sovacool/Documents/Zotero/storage/VGVJYWT5/194958.html}
}

@article{oh_generalizable_2018,
  title = {A {{Generalizable}}, {{Data-Driven Approach}} to {{Predict Daily Risk}} of {{Clostridium}} Difficile {{Infection}} at {{Two Large Academic Health Centers}}},
  author = {Oh, Jeeheh and Makar, Maggie and Fusco, Christopher and McCaffrey, Robert and Rao, Krishna and Ryan, Erin E. and Washer, Laraine and West, Lauren R. and Young, Vincent B. and Guttag, John and Hooper, David C. and Shenoy, Erica S. and Wiens, Jenna},
  year = {2018},
  month = apr,
  journal = {Infect Control Hosp Epidemiol},
  volume = {39},
  number = {4},
  pages = {425--433},
  issn = {0899-823X},
  doi = {10.1017/ice.2018.16},
  url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6421072/},
  urldate = {2023-02-16},
  abstract = {OBJECTIVE. An estimated 293,300 healthcare-associated cases of Clostridium difficile infection (CDI) occur annually in the United States. To date, research has focused on developing risk prediction models for CDI that work well across institutions. However, this one-size-fits-all approach ignores important hospital-specific factors. We focus on a generalizable method for building facility-specific models. We demonstrate the applicability of the approach using electronic health records (EHR) from the University of Michigan Hospitals (UM) and the Massachusetts General Hospital (MGH). METHODS. We utilized EHR data from 191,014 adult admissions to UM and 65,718 adult admissions to MGH. We extracted patient demographics, admission details, patient history, and daily hospitalization details, resulting in 4,836 features from patients at UM and 1,837 from patients at MGH. We used L2 regularized logistic regression to learn the models, and we measured the discriminative performance of the models on held-out data from each hospital. RESULTS. Using the UM and MGH test data, the models achieved area under the receiver operating characteristic curve (AUROC) values of 0.82 (95\% confidence interval [CI], 0.80\textendash 0.84) and 0.75 ( 95\% CI, 0.73\textendash 0.78), respectively. Some predictive factors were shared between the 2 models, but many of the top predictive factors differed between facilities. CONCLUSION. A data-driven approach to building models for estimating daily patient risk for CDI was used to build institution-specific models at 2 large hospitals with different patient populations and EHR systems. In contrast to traditional approaches that focus on developing models that apply across hospitals, our generalizable approach yields risk-stratification models tailored to an institution. These hospital-specific models allow for earlier and more accurate identification of high-risk patients and better targeting of infection prevention strategies.},
  pmcid = {PMC6421072},
  pmid = {29576042},
  file = {/Users/sovacool/Documents/Zotero/storage/5AHBCXIY/Oh et al_2018_A Generalizable, Data-Driven Approach to Predict Daily Risk of Clostridium.pdf}
}

@book{oksanen_vegan_2023,
  title = {Vegan: {{Community Ecology Package}}},
  author = {Oksanen, Jari and Simpson, Gavin L. and Blanchet, F. Guillaume and Kindt, Roeland and Legendre, Pierre and Minchin, Peter R. and O'Hara, R. B. and Solymos, Peter and Stevens, M. Henry H. and Szoecs, Eduard and Wagner, Helene and Barbour, Matt and Bedward, Michael and Bolker, Ben and Borcard, Daniel and Carvalho, Gustavo and Chirico, Michael and Caceres, Miquel De and Durand, Sebastien and Evangelista, Heloisa Beatriz Antoniazi and FitzJohn, Rich and Friendly, Michael and Furneaux, Brendan and Hannigan, Geoffrey and Hill, Mark O. and Lahti, Leo and McGlinn, Dan and Ouellette, Marie-Helene and Cunha, Eduardo Ribeiro and Smith, Tyler and Stier, Adrian and Braak, Cajo J. F. Ter and Weedon, James},
  year = {2023},
  url = {https://github.com/vegandevs/vegan}
}

@article{otles_clostridioides_2023,
  title = {Clostridioides Difficile Infection Surveillance in Intensive Care Units and Oncology Wards Using Machine Learning},
  author = {{\"O}tle{\c s}, Erkin and Balczewski, Emily A. and Keidan, Micah and Oh, Jeeheh and Patel, Alieysa and Young, Vincent B. and Rao, Krishna and Wiens, Jenna},
  year = {2023},
  month = apr,
  journal = {Infection Control \& Hospital Epidemiology},
  pages = {1--6},
  publisher = {{Cambridge University Press}},
  issn = {0899-823X, 1559-6834},
  doi = {10.1017/ice.2023.54},
  url = {https://www.cambridge.org/core/journals/infection-control-and-hospital-epidemiology/article/clostridioides-difficile-infection-surveillance-in-intensive-care-units-and-oncology-wards-using-machine-learning/049BA806578391E5DE86FFCD574808BB},
  urldate = {2023-05-03},
  abstract = {Objective: Screening individuals admitted to the hospital for Clostridioides difficile presents opportunities to limit transmission and hospital-onset C. difficile infection (HO-CDI). However, detection from rectal swabs is resource intensive. In contrast, machine learning (ML) models may accurately assess patient risk without significant resource usage. In this study, we compared the effectiveness of swab surveillance to daily risk estimates produced by an ML model to identify patients who will likely develop HO-CDI in the intensive care unit (ICU) setting. Design: A prospective cohort study was conducted with patient carriage of toxigenic C. difficile identified by rectal swabs analyzed by anaerobic culture and polymerase chain reaction (PCR). A previously validated ML model using electronic health record data generated daily risk of HO-CDI for every patient. Swab results and risk predictions were compared to the eventual HO-CDI status. Patients: Adult inpatient admissions taking place in University of Michigan Hospitals' medical and surgical intensive care units and oncology wards between June 6th and October 8th, 2020. Results: In total, 2,979 admissions, representing 2,044 patients, were observed over the course of the study period, with 39 admissions developing HO-CDIs. Swab surveillance identified 9 true-positive and 87 false-positive HO-CDIs. The ML model identified 9 true-positive and 226 false-positive HO-CDIs; 8 of the true-positives identified by the model differed from those identified by the swab surveillance. Conclusion: With limited resources, an ML model identified the same number of HO-CDI admissions as swab-based surveillance, though it generated more false-positives. The patients identified by the ML model were not yet colonized with C. difficile. Additionally, the ML model identifies at-risk admissions before disease onset, providing opportunities for prevention.},
  langid = {english},
  file = {/Users/sovacool/Documents/Zotero/storage/LZQXNTDQ/tle et al_2023_Clostridioides difficile infection surveillance in intensive care units and.pdf}
}

@article{peirce_numerical_1884,
  title = {The {{Numerical Measure}} of the {{Success}} of {{Predictions}}},
  author = {Peirce, C. S.},
  year = {1884},
  month = nov,
  journal = {Science},
  volume = {ns-4},
  number = {93},
  pages = {453--454},
  issn = {0036-8075, 1095-9203},
  doi = {10.1126/science.ns-4.93.453.b},
  url = {https://www.science.org/doi/10.1126/science.ns-4.93.453.b},
  urldate = {2023-05-25},
  langid = {english},
  file = {/Users/sovacool/Documents/Zotero/storage/JV4FB59U/Peirce - 1884 - The Numerical Measure of the Success of Prediction.pdf}
}

@article{perry_external_2022,
  title = {External {{Validation}} and {{Comparison}} of {{{\emph{Clostridioides}}}}{\emph{ Difficile}} {{Severity Scoring Systems}}},
  author = {Perry, D Alexander and Shirley, Daniel and Micic, Dejan and Patel, Pratish C and Putler, Rosemary and Menon, Anitha and Young, Vincent B and Rao, Krishna},
  year = {2022},
  month = jun,
  journal = {Clinical Infectious Diseases},
  volume = {74},
  number = {11},
  pages = {2028--2035},
  issn = {1058-4838},
  doi = {10.1093/cid/ciab737},
  url = {https://doi.org/10.1093/cid/ciab737},
  urldate = {2023-06-05},
  abstract = {Many models have been developed to predict severe outcomes from Clostridioides difficile infection (CDI). These models are usually developed at a single institution and largely are not externally validated. Our aim in this study was to validate previously published risk scores in a multicenter cohort of patients with CDI.This was a retrospective study on 4 inpatient cohorts with CDI from 3 distinct sites: the universities of Michigan (2010\textendash 2012 and 2016), Chicago (2012), and Wisconsin (2012). The primary composite outcome was admission to an intensive care unit, colectomy, and/or death attributed to CDI within 30 days of positive testing. Both within each cohort and combined across all cohorts, published CDI severity scores were assessed and compared to each other and the Infectious Diseases Society of America (IDSA) guideline definitions of severe and fulminant CDI.A total of 3646 patients were included for analysis. Including the 2 IDSA guideline definitions, 14 scores were assessed. Performance of scores varied within each cohort and in the combined set (mean area under the receiver operator characteristic curve [AuROC], 0.61; range, 0.53\textendash 0.66). Only half of the scores had performance at or better than IDSA severe and fulminant definitions (AuROCs of 0.64 and 0.63, respectively). Most of the scoring systems had more false than true positives in the combined set (mean, 81.5\%; range, 0\%\textendash 91.5\%).No published CDI severity score showed stable, good predictive ability for adverse outcomes across multiple cohorts/institutions or in a combined multicenter cohort.},
  file = {/Users/sovacool/Documents/Zotero/storage/FSZNMJ3N/Perry et al_2022_External Validation and Comparison of Clostridioides difficile Severity Scoring.pdf;/Users/sovacool/Documents/Zotero/storage/LA3XAYEE/6359793.html}
}

@article{poduval_clostridium_2000,
  title = {{\emph{Clostridium }}{{{\emph{Difficile}}}} and {{Vancomycin-Resistant Enterococcus}}: {{The New Nosocomial Alliance}}},
  shorttitle = {Clostridium {{Difficileand Vancomycin-Resistant Enterococcus}}},
  author = {Poduval, Rajiv D. and Kamath, Ramdas P. and Corpuz, Marilou and Norkus, Edward P. and Pitchumoni, C. S.},
  year = {2000},
  month = dec,
  journal = {Official journal of the American College of Gastroenterology | ACG},
  volume = {95},
  number = {12},
  pages = {3513},
  issn = {0002-9270},
  doi = {10.1111/j.1572-0241.2000.03291.x},
  url = {https://journals.lww.com/ajg/Abstract/2000/12000/Clostridium_Difficileand_Vancomycin_Resistant.28.aspx},
  urldate = {2023-06-02},
  abstract = {OBJECTIVES:~           The aims of this study were to determine the frequency of the association between Clostridium difficile (C. difficile) and vancomycin-resistant Enterococcus (VRE) and delineate the role of C. difficile coinfection as a predictor of VRE infection versus colonization and adverse outcome.           METHODS:~           Patients with both C. difficile colitis and VRE (CD/VRE) were compared to patients with VRE alone with regard to demographics, comorbidity, prior antibiotic therapy, and coinfection with methicillin-resistant Staphylococcus aureus and funguria. C. difficile as a predictor of VRE infection (VRE-I) versus colonization (VRE-C) and adverse outcome was also studied.           RESULTS:~           Eighty-nine patients with VRE infection or colonization were studied. This included 31 cases of VRE-I and 58 VRE-C. C. difficile was isolated in 17 (19.1\%) of patients; of these C. difficile was isolated before VRE in 9 patients and after VRE in 8. The two groups did not differ in age, residence, or comorbidity. C. difficile coinfection was not predictive of VRE-I versus VRE-C, nor was it associated with increased length of stay or mortality. However, the mortality rates in both groups was high, around 30\%. A significant association was noted between the use of vancomycin and metronidazole (before the isolation of VRE) and C. difficile coinfection (p= 0.03 and p= 0.001, respectively). A high incidence of nosocomial coinfection with methicillin-resistant Staphylococcus aureus, funguria, and gram-negative sepsis was noted in both groups; the association with funguria was statistically significant (p= 0.029).           CONCLUSIONS:~           In conclusion, C. difficile coinfection is common in patients with VRE infection or colonization and is significantly associated with other nosocomial dilemmas like funguria. This may result in the emergence of highly virulent pathogens including vancomycin-resistant C. difficile, posing new challenges in the management of nosocomial diarrheas.},
  langid = {american},
  file = {/Users/sovacool/Documents/Zotero/storage/23PWZZ9R/Clostridium_Difficileand_Vancomycin_Resistant.28.html}
}

@article{polage_uncovering_2021,
  title = {Uncovering the {{Harms}} of {{Treating Clostridioides}} Difficile {{Colonization}}},
  author = {Polage, Christopher R. and Turner, Nicholas A.},
  year = {2021},
  month = jan,
  journal = {mSphere},
  volume = {6},
  number = {1},
  pages = {10.1128/msphere.01296-20},
  publisher = {{American Society for Microbiology}},
  doi = {10.1128/msphere.01296-20},
  url = {https://journals.asm.org/doi/10.1128/mSphere.01296-20},
  urldate = {2023-06-03},
  abstract = {Patients with toxin-negative Clostridioides difficile-positive diarrhea are often treated with oral vancomycin with the assumption that treatment is more beneficial than harmful. However, this hypothesis has never been formally tested, and recent studies suggest that most such patients recover quickly without treatment and can be colonized rather than infected. Fishbein et al. conducted a prospective, placebo-controlled randomized trial to systematically evaluate the effects, risks, and benefits of oral vancomycin in these patients (S. R. S. Fishbein, T. Hink, K. A. Reske, C. Cass, et al., mSphere 6:e00936-20, 2020, https://doi.org/10.1128/mSphere.00936-20). Although small, the results are intriguing and suggest the adverse antibiotic-induced effects of vancomycin outweigh the clinical benefit when colonization is more likely than disease.},
  file = {/Users/sovacool/Documents/Zotero/storage/8CNR2L88/Polage_Turner_2021_Uncovering the Harms of Treating Clostridioides difficile Colonization.pdf}
}

@article{quast_silva_2013,
  title = {The {{SILVA}} Ribosomal {{RNA}} Gene Database Project: Improved Data Processing and Web-Based Tools},
  shorttitle = {The {{SILVA}} Ribosomal {{RNA}} Gene Database Project},
  author = {Quast, Christian and Pruesse, Elmar and Yilmaz, Pelin and Gerken, Jan and Schweer, Timmy and Yarza, Pablo and Peplies, J{\"o}rg and Gl{\"o}ckner, Frank Oliver},
  year = {2013},
  month = jan,
  journal = {Nucleic Acids Research},
  volume = {41},
  number = {D1},
  pages = {D590-D596},
  issn = {0305-1048},
  doi = {10.1093/nar/gks1219},
  url = {https://doi.org/10.1093/nar/gks1219},
  urldate = {2021-03-05},
  abstract = {SILVA (from Latin silva, forest, http://www.arb-silva.de) is a comprehensive web resource for up to date, quality-controlled databases of aligned ribosomal RNA (rRNA) gene sequences from the Bacteria, Archaea and Eukaryota domains and supplementary online services. The referred database release 111 (July 2012) contains 3 194 778 small subunit and 288 717 large subunit rRNA gene sequences. Since the initial description of the project, substantial new features have been introduced, including advanced quality control procedures, an improved rRNA gene aligner, online tools for probe and primer evaluation and optimized browsing, searching and downloading on the website. Furthermore, the extensively curated SILVA taxonomy and the new non-redundant SILVA datasets provide an ideal reference for high-throughput classification of data from next-generation sequencing approaches.},
  file = {/Users/sovacool/Library/CloudStorage/GoogleDrive-sovacool@umich.edu/Shared drives/umich-shared/Zotero/Quast_et_al_2013_Nucleic_Acids_Research.pdf}
}

@manual{r_core_team_r_2023,
  type = {Manual},
  title = {R: {{A}} Language and Environment for Statistical Computing},
  author = {{R Core Team}},
  year = {2023},
  address = {{Vienna, Austria}},
  institution = {{R Foundation for Statistical Computing}},
  url = {https://www.R-project.org/}
}

@article{rao_clostridium_2015,
  title = {{\emph{Clostridium Difficile}} {{Ribotype}} 027: {{Relationship}} to {{Age}}, {{Detectability}} of {{Toxins A}} or {{B}} in {{Stool With Rapid Testing}}, {{Severe Infection}}, and {{Mortality}}},
  shorttitle = {Clostridium Difficile {{Ribotype}} 027},
  author = {Rao, Krishna and Micic, Dejan and Natarajan, Mukil and Winters, Spencer and Kiel, Mark J. and Walk, Seth T. and Santhosh, Kavitha and Mogle, Jill A. and Galecki, Andrzej T. and LeBar, William and Higgins, Peter D. R. and Young, Vincent B. and Aronoff, David M.},
  year = {2015},
  month = jul,
  journal = {Clinical Infectious Diseases},
  volume = {61},
  number = {2},
  pages = {233--241},
  issn = {1058-4838},
  doi = {10.1093/cid/civ254},
  url = {https://doi.org/10.1093/cid/civ254},
  urldate = {2023-05-12},
  abstract = {Background.{$\quad$}Clostridium difficile infection (CDI) can cause severe disease and death, especially in older adults. A better understanding of risk factors for adverse outcomes is needed. This study tests the hypotheses that infection with specific ribotypes and presence of stool toxins independently associate with severity and constructs predictive models of adverse outcomes.Methods.{$\quad$}Cases of non-recurrent CDI were prospectively included after positive stool tests for toxins A and/or B by enzyme immunoassay (EIA) or tcdB by polymerase chain reaction. Outcomes included severe CDI (intensive care unit admission, colectomy, or death attributable to CDI within 30 days of diagnosis) and 30-day all-cause mortality. Adjusted models were developed to test hypotheses and predict outcomes.Results.{$\quad$}In total, 1144 cases were included. The toxin EIA was positive in 37.2\% and 35.6\% of patients were of age \&gt;65 years. One of the 137 unique ribotypes was ribotype 027 (16.2\%). Detectable stool toxin did not associate with outcomes. Adjusting for covariates, including age, Ribotype 027 was a significant predictor of severe CDI (90 cases; odds ratio [OR], 1.73; 95\% confidence interval [CI], 1.03\textendash 2.89; P = .037) and mortality (89 cases; OR, 2.02; 95\% CI, 1.19\textendash 3.43; P = .009). Concurrent antibiotic use associated with both outcomes. Both multivariable predictive models had excellent performance (area under the curve \&gt;0.8).Conclusions.{$\quad$}Detection of stool toxin A and/or B by EIA does not predict severe CDI or mortality. Infection with ribotype 027 independently predicts severe CDI and mortality. Use of concurrent antibiotics is a potentially modifiable risk factor for severe CDI.},
  file = {/Users/sovacool/Documents/Zotero/storage/7TGC7U4N/Rao et al_2015_Clostridium difficile Ribotype 027.pdf;/Users/sovacool/Documents/Zotero/storage/NCG84DAK/328953.html}
}

@article{rembold_number_1998,
  title = {Number Needed to Screen: Development of a Statistic for Disease Screening},
  shorttitle = {Number Needed to Screen},
  author = {Rembold, Christopher M.},
  year = {1998},
  month = aug,
  journal = {BMJ},
  volume = {317},
  number = {7154},
  pages = {307--312},
  publisher = {{British Medical Journal Publishing Group}},
  issn = {0959-8138, 1468-5833},
  doi = {10.1136/bmj.317.7154.307},
  url = {https://www.bmj.com/content/317/7154/307},
  urldate = {2023-05-10},
  abstract = {Objectives: To develop the number needed to screen, a new statistic to overcome inappropriate national strategies for disease screening.Number needed to screen is defined as the number of people that need to be screened for a given duration to prevent one death or adverse event. Design: Number needed to screen was calculated from clinical trials that directly measured the effect of a screening strategy. From clinical trials that measured treatment benefit, the number needed to screen was estimated as the number needed to treat from the trial divided by the prevalence of heretofore unrecognised or untreated disease. Directly calculated values were then compared with estimate number needed to screen values. Subjects: Standard literature review. Results: For prevention of total mortality the most effective screening test was a lipid profile. The estimated number needed to screen for dyslipidaemia (low density lipoprotein cholesterol concentration {$>$}4.14 mmol/1) was 418 if detection was followed by pravastatin treatment for 5 years. This indicates that one death in 5 years could be prevented by screening 418 people. The estimated number needed to screen for hypertension was between 274 and 1307 for 5 years (for 10 mm Hg and 6 mm Hg diastolic blood pressure reduction respectively) if detection was followed by treatment based on a diuretic. Screening with haemoccult testing and mammography significantly decreased cancer specific, but not total, mortality. The number needed to screen for haemoccult screening to prevent a death from colon cancer was 1374 for 5 years, and the number needed to screen for mammography to prevent a death from breast cancer was 2451 for 5 years for women aged 50-59. Conclusion: These data allow the clinician to prioritise screening strategies. Of the screening strategies evaluated, screening for, and treatment of, dyslipidaemia and hypertension seem to produce the largest clinical benefit.},
  chapter = {Paper},
  copyright = {\textcopyright{} 1998 BMJ Publishing Group Ltd.},
  langid = {english},
  pmid = {9685274},
  file = {/Users/sovacool/Documents/Zotero/storage/3HXAMRUY/Rembold_1998_Number needed to screen.pdf}
}

@article{ressler_defining_2021,
  title = {Defining the Black Box: A Narrative Review of Factors Associated with Adverse Outcomes from Severe {{{\emph{Clostridioides}}}}{\emph{ Difficile}} Infection},
  shorttitle = {Defining the Black Box},
  author = {Ressler, Adam and Wang, Joyce and Rao, Krishna},
  year = {2021},
  month = jan,
  journal = {Therap Adv Gastroenterol},
  volume = {14},
  pages = {17562848211048127},
  publisher = {{SAGE Publications Ltd STM}},
  issn = {1756-2848},
  doi = {10.1177/17562848211048127},
  url = {https://doi.org/10.1177/17562848211048127},
  urldate = {2023-06-03},
  abstract = {In the United States, Clostridioides difficile infection (CDI) is the leading cause of healthcare-associated infection, affecting nearly half a million people and resulting in more than 20,000 in-hospital deaths every year. It is therefore imperative to better characterize the intricate interplay between C. difficile microbial factors, host immunologic signatures, and clinical features that are associated with adverse outcomes of severe CDI. In this narrative review, we discuss the implications of C. difficile genetics and virulence factors in the molecular epidemiology of CDI, and the utility of early biomarkers in predicting the clinical trajectory of patients at risk of developing severe CDI. Furthermore, we identify associations between host immune factors and CDI outcomes in both animal models and human studies. Next, we highlight clinical factors including renal dysfunction, aging, blood biomarkers, level of care, and chronic illnesses that can affect severe CDI diagnosis and outcome. Finally, we present our perspectives on two specific treatments pertinent to patient outcomes: metronidazole administration and surgery. Together, this review explores the various venues of CDI research and highlights the importance of integrating microbial, host, and clinical data to help clinicians make optimal treatment decisions based on accurate prediction of disease progression.},
  langid = {english},
  file = {/Users/sovacool/Documents/Zotero/storage/4DL93BCM/Ressler et al_2021_Defining the black box.pdf}
}

@article{reveles_fidaxomicin_2017,
  title = {Fidaxomicin versus {{Vancomycin}} as a {{First-Line Treatment}} for {{{\emph{Clostridium}}}}{\emph{ Difficile}}\textendash{{Associated Diarrhea}} in {{Specific Patient Populations}}: {{A Pharmacoeconomic Evaluation}}},
  shorttitle = {Fidaxomicin versus {{Vancomycin}} as a {{First-Line Treatment}} for {{Clostridium}} Difficile\textendash{{Associated Diarrhea}} in {{Specific Patient Populations}}},
  author = {Reveles, Kelly R. and Backo, Jennifer L. and Corvino, Frank A. and Zivkovic, Marko and Broderick, Kelly C.},
  year = {2017},
  journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  volume = {37},
  number = {12},
  pages = {1489--1497},
  issn = {1875-9114},
  doi = {10.1002/phar.2049},
  url = {https://onlinelibrary.wiley.com/doi/abs/10.1002/phar.2049},
  urldate = {2023-06-05},
  abstract = {Objectives The reduction in recurrent Clostridium difficile\textendash associated diarrhea (CDAD) with fidaxomicin therapy may reduce hospital readmissions and lead to lower overall CDAD costs. However, studies assessing the cost-effectiveness of fidaxomicin as first-line therapy from the U.S. hospital perspective are lacking. This study evaluated the costs associated with utilizing fidaxomicin or vancomycin as a first-line therapy for CDAD in specific patient populations from a U.S. hospital perspective. Methods A decision-analytic model was developed to estimate total costs (hospitalization and drug costs) associated with using fidaxomicin or vancomycin as first-line therapy for a first episode and up to two recurrences of CDAD in five patient populations: general population, elderly, patients receiving concomitant antibiotics, and patients with renal impairment or cancer. Results The total cost of CDAD treatment using fidaxomicin first line in the general population was \textbackslash 14,442 per patient versus \textbackslash 14,179 per patient with vancomycin first line. In subgroup analyses, fidaxomicin use resulted in total hospital cost savings of \textbackslash 616 per patient in patients with cancer and \textbackslash 312 in patients with concomitant antibiotic use; vancomycin use was associated with total hospital cost savings of \textbackslash 243 per patient in the elderly and \textbackslash 371 in patients with renal impairment. Conclusions Fidaxomicin as first-line CDAD therapy is associated with similar total costs as compounded vancomycin oral solution in the general population. In elderly and renally impaired patients, slight increases in hospital cost were observed with fidaxomicin therapy, and in patients with cancer or concomitant antibiotic use, hospital cost savings were observed.},
  langid = {english},
  keywords = {Clostridium difficile,costs,fidaxomicin,vancomycin},
  file = {/Users/sovacool/Documents/Zotero/storage/X64LKLBK/Reveles et al_2017_Fidaxomicin versus Vancomycin as a First-Line Treatment for Clostridium.pdf;/Users/sovacool/Documents/Zotero/storage/YL65IKIZ/phar.html}
}

@article{saito_precision-recall_2015,
  title = {The {{Precision-Recall Plot Is More Informative}} than the {{ROC Plot When Evaluating Binary Classifiers}} on {{Imbalanced Datasets}}},
  author = {Saito, Takaya and Rehmsmeier, Marc},
  year = {2015},
  month = mar,
  journal = {PLOS ONE},
  volume = {10},
  number = {3},
  pages = {e0118432},
  publisher = {{Public Library of Science}},
  issn = {1932-6203},
  doi = {10.1371/journal.pone.0118432},
  url = {https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0118432},
  urldate = {2022-02-06},
  abstract = {Binary classifiers are routinely evaluated with performance measures such as sensitivity and specificity, and performance is frequently illustrated with Receiver Operating Characteristics (ROC) plots. Alternative measures such as positive predictive value (PPV) and the associated Precision/Recall (PRC) plots are used less frequently. Many bioinformatics studies develop and evaluate classifiers that are to be applied to strongly imbalanced datasets in which the number of negatives outweighs the number of positives significantly. While ROC plots are visually appealing and provide an overview of a classifier's performance across a wide range of specificities, one can ask whether ROC plots could be misleading when applied in imbalanced classification scenarios. We show here that the visual interpretability of ROC plots in the context of imbalanced datasets can be deceptive with respect to conclusions about the reliability of classification performance, owing to an intuitive but wrong interpretation of specificity. PRC plots, on the other hand, can provide the viewer with an accurate prediction of future classification performance due to the fact that they evaluate the fraction of true positives among positive predictions. Our findings have potential implications for the interpretation of a large number of studies that use ROC plots on imbalanced datasets.},
  langid = {english},
  keywords = {Bioinformatics,Caenorhabditis elegans,Exponential functions,Genome-wide association studies,Interpolation,Measurement,MicroRNAs,Support vector machines},
  file = {/Users/sovacool/Library/CloudStorage/GoogleDrive-sovacool@umich.edu/Shared drives/umich-shared/Zotero/Saito_et_al_2015_PLOS_ONE.pdf}
}

@article{saund_genetic_2020,
  title = {Genetic {{Determinants}} of {{Trehalose Utilization Are Not Associated With Severe Clostridium}} Difficile {{Infection Outcome}}},
  author = {Saund, Katie and Rao, Krishna and Young, Vincent B and Snitkin, Evan S},
  year = {2020},
  month = jan,
  journal = {Open Forum Infectious Diseases},
  volume = {7},
  number = {1},
  pages = {ofz548},
  issn = {2328-8957},
  doi = {10.1093/ofid/ofz548},
  url = {https://doi.org/10.1093/ofid/ofz548},
  urldate = {2022-11-28},
  abstract = {In a case\textendash control study of patients with Clostridium difficile infection, we found no statistically significant association between the presence of trehalose utilization variants in infecting C. difficile strains and development of severe infection outcome. These results do not support trehalose utilization conferring enhanced virulence in the context of human C. difficile infections.},
  file = {/Users/sovacool/Documents/Zotero/storage/QBG2ECW7/Saund et al_2020_Genetic Determinants of Trehalose Utilization Are Not Associated With Severe.pdf;/Users/sovacool/Documents/Zotero/storage/TGTKP8GW/5696590.html}
}

@article{schloss_introducing_2009,
  title = {Introducing Mothur: {{Open-Source}}, Platform-Independent, Community-Supported Software for Describing and Comparing Microbial Communities},
  author = {Schloss, Patrick D. and Westcott, Sarah L. and Ryabin, Thomas and Hall, Justine R. and Hartmann, Martin and Hollister, Emily B. and Lesniewski, Ryan A. and Oakley, Brian B. and Parks, Donovan H. and Robinson, Courtney J. and Sahl, Jason W. and Stres, Blaz and Thallinger, Gerhard G. and Van Horn, David J. and Weber, Carolyn F.},
  year = {2009},
  journal = {Applied and Environmental Microbiology},
  volume = {75},
  number = {23},
  eprint = {https://aem.asm.org/content/75/23/7537.full.pdf},
  pages = {7537--7541},
  publisher = {{American Society for Microbiology Journals}},
  issn = {0099-2240},
  doi = {10.1128/AEM.01541-09},
  abstract = {mothur aims to be a comprehensive software package that allows users to use a single piece of software to analyze community sequence data. It builds upon previous tools to provide a flexible and powerful software package for analyzing sequencing data. As a case study, we used mothur to trim, screen, and align sequences; calculate distances; assign sequences to operational taxonomic units; and describe the {$\alpha$} and {$\beta$} diversity of eight marine samples previously characterized by pyrosequencing of 16S rRNA gene fragments. This analysis of more than 222,000 sequences was completed in less than 2 h with a laptop computer.},
  file = {/Users/sovacool/Library/CloudStorage/GoogleDrive-sovacool@umich.edu/Shared drives/umich-shared/Zotero/Schloss_et_al_2009_Applied_and_Environmental_Microbiology.pdf}
}

@article{schubert_microbiome_2014,
  title = {Microbiome {{Data Distinguish Patients}} with {{{\emph{Clostridium}}}}{\emph{ Difficile}} {{Infection}} and {{Non-}}{{{\emph{C}}}}{\emph{. Difficile}}-{{Associated Diarrhea}} from {{Healthy Controls}}},
  author = {Schubert, Alyxandria M. and Rogers, Mary A. M. and Ring, Cathrin and Mogle, Jill and Petrosino, Joseph P. and Young, Vincent B. and Aronoff, David M. and Schloss, Patrick D.},
  year = {2014},
  month = jul,
  journal = {mBio},
  volume = {5},
  number = {3},
  publisher = {{American Society for Microbiology}},
  issn = {2150-7511},
  doi = {10.1128/mBio.01021-14},
  url = {https://mbio.asm.org/content/5/3/e01021-14},
  urldate = {2020-05-01},
  abstract = {Antibiotic usage is the most commonly cited risk factor for hospital-acquired Clostridium difficile infections (CDI). The increased risk is due to disruption of the indigenous microbiome and a subsequent decrease in colonization resistance by the perturbed bacterial community; however, the specific changes in the microbiome that lead to increased risk are poorly understood. We developed statistical models that incorporated microbiome data with clinical and demographic data to better understand why individuals develop CDI. The 16S rRNA genes were sequenced from the feces of 338 individuals, including cases, diarrheal controls, and nondiarrheal controls. We modeled CDI and diarrheal status using multiple clinical variables, including age, antibiotic use, antacid use, and other known risk factors using logit regression. This base model was compared to models that incorporated microbiome data, using diversity metrics, community types, or specific bacterial populations, to identify characteristics of the microbiome associated with CDI susceptibility or resistance. The addition of microbiome data significantly improved our ability to distinguish CDI status when comparing cases or diarrheal controls to nondiarrheal controls. However, only when we assigned samples to community types was it possible to differentiate cases from diarrheal controls. Several bacterial species within the Ruminococcaceae, Lachnospiraceae, Bacteroides, and Porphyromonadaceae were largely absent in cases and highly associated with nondiarrheal controls. The improved discriminatory ability of our microbiome-based models confirms the theory that factors affecting the microbiome influence CDI. IMPORTANCE The gut microbiome, composed of the trillions of bacteria residing in the gastrointestinal tract, is responsible for a number of critical functions within the host. These include digestion, immune system stimulation, and colonization resistance. The microbiome's role in colonization resistance, which is the ability to prevent and limit pathogen colonization and growth, is key for protection against Clostridium difficile infections. However, the bacteria that are important for colonization resistance have not yet been elucidated. Using statistical modeling techniques and different representations of the microbiome, we demonstrated that several community types and the loss of several bacterial populations, including Bacteroides, Lachnospiraceae, and Ruminococcaceae, are associated with CDI. Our results emphasize the importance of considering the microbiome in mediating colonization resistance and may also direct the design of future multispecies probiotic therapies.},
  chapter = {Research Article},
  copyright = {Copyright \textcopyright{} 2014 Schubert et al.. This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-ShareAlike 3.0 Unported license, which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original author and source are credited.},
  langid = {english},
  pmid = {24803517},
  file = {/Users/sovacool/Documents/Zotero/storage/PDCWU5ZG/Schubert et al_2014_Microbiome Data Distinguish Patients with Clostridium difficile Infection and.pdf;/Users/sovacool/Library/CloudStorage/GoogleDrive-sovacool@umich.edu/Shared drives/umich-shared/Zotero/Schubert_et_al_2014_mBio.pdf}
}

@article{seekatz_dynamics_2016,
  title = {Dynamics of the Fecal Microbiome in Patients with Recurrent and Nonrecurrent {{Clostridium}} Difficile Infection},
  author = {Seekatz, Anna Maria and Rao, Krishna and Santhosh, Kavitha and Young, Vincent Bensan},
  year = {2016},
  month = apr,
  journal = {Genome Medicine},
  volume = {8},
  number = {1},
  pages = {47},
  issn = {1756-994X},
  doi = {10.1186/s13073-016-0298-8},
  url = {https://doi.org/10.1186/s13073-016-0298-8},
  urldate = {2021-08-27},
  abstract = {Recurrent Clostridium difficile infection (CDI) remains problematic, with up to 30 \% of individuals diagnosed with primary CDI experiencing at least one episode of recurrence. The success of microbial-based therapeutics, such as fecal microbiota transplantation, for the treatment of recurrent CDI underscores the importance of restoring the microbiota. However, few studies have looked at the microbial factors that contribute to the development of recurrent disease. Here we compare microbial changes over time in patients with or without recurrence to identify microbial signatures associated with the development of recurrence.},
  keywords = {Clostridium Difficile Infection,Fecal Microbiota,Fecal Microbiota Transplantation,Generalize Estimate Equation,Recurrent Patient},
  file = {/Users/sovacool/Library/CloudStorage/GoogleDrive-sovacool@umich.edu/Shared drives/umich-shared/Zotero/Seekatz_et_al_2016_Genome_Medicine.pdf}
}

@article{seekatz_role_2022,
  title = {The Role of the Gut Microbiome in Colonization Resistance and Recurrent {{Clostridioides}} Difficile Infection},
  author = {Seekatz, Anna Maria and Safdar, Nasia and Khanna, Sahil},
  year = {2022},
  month = jan,
  journal = {Therap Adv Gastroenterol},
  volume = {15},
  pages = {17562848221134396},
  publisher = {{SAGE Publications Ltd STM}},
  issn = {1756-2848},
  doi = {10.1177/17562848221134396},
  url = {https://doi.org/10.1177/17562848221134396},
  urldate = {2023-06-06},
  abstract = {The species composition of the human gut microbiota is related to overall health, and a healthy gut microbiome is crucial in maintaining colonization resistance against pathogens. Disruption of gut microbiome composition and functionality reduces colonization resistance and has been associated with several gastrointestinal and non-gastrointestinal diseases. One prime example is Clostridioides difficile infection (CDI) and subsequent recurrent infections that occur after the development of systemic antibiotic-related dysbiosis. Standard-of-care antibiotics used for both acute and recurrent infections do not address dysbiosis and often worsen the condition. Moreover, monoclonal antibodies, recommended in conjunction with standard-of-care antibiotics for the prevention of recurrent CDI in patients at high risk of recurrence, reduce recurrences but do not address the underlying dysbiosis. Fecal microbiota transplantation (FMT) is an evolving therapeutic strategy in which microbes are harvested from healthy donor stool and transplanted into the gut of a recipient to restore the gut microbiome. Although effective in the prevention of recurrent CDI, some existing challenges include screening and the standardization of stool acquisition and processing. Recent safety alerts by the US Food and Drug Administration raised concern about the possibility of transmission of multidrug-resistant organisms or severe acute respiratory syndrome coronavirus 2 via FMT. Increased knowledge that microbes are beneficial in restoring the gut microbiome has led to the clinical development of several newer biotherapeutic formulations that are more regulated than FMT, which may allow for improved restoration of the gut microbiome and prevention of CDI recurrence. This review focuses on mechanisms by which gut microbiome restoration could influence colonization resistance against the pathogen C. difficile.},
  langid = {english},
  file = {/Users/sovacool/Documents/Zotero/storage/SU2UKDBV/Seekatz et al_2022_The role of the gut microbiome in colonization resistance and recurrent.pdf}
}

@article{shannon_mathematical_1948,
  title = {A {{Mathematical Theory}} of {{Communication}}},
  author = {Shannon, Claude E.},
  year = {1948},
  url = {https://web.archive.org/web/19980715013250/http://cm.bell-labs.com/cm/ms/what/shannonday/shannon1948.pdf},
  urldate = {2023-03-28},
  file = {/Users/sovacool/Documents/Zotero/storage/W68BSDRB/Shannon - 1948 - A Mathematical Theory of Communication.pdf}
}

@article{simpson_measurement_1949,
  title = {Measurement of {{Diversity}}},
  author = {Simpson, E. H.},
  year = {1949},
  month = apr,
  journal = {Nature},
  volume = {163},
  number = {4148},
  pages = {688--688},
  publisher = {{Nature Publishing Group}},
  issn = {1476-4687},
  doi = {10.1038/163688a0},
  url = {https://www.nature.com/articles/163688a0},
  urldate = {2023-03-28},
  abstract = {THE 'characteristic' defined by Yule1 and the 'index of diversity' defined by Fisher2 are two measures of the degree of concentration or diversity achieved when the individuals of a population are classified into groups. Both are defined as statistics to be calculated from sample data and not in terms of population constants. The index of diversity has so far been used chiefly with the logarithmic distribution. It cannot be used everywhere, as it does not always give values which are independent of sample size ; it cannot do so, for example, when applied to an infinite population of individuals classified into a finite number of groups. Williams3 has pointed out a relationship between the characteristic and the index of diversity when both are applied to a logarithmic distribution. The present purpose is to define and examine a measure of concentration in terms of population constants.},
  copyright = {1949 Nature Publishing Group},
  langid = {english},
  keywords = {Humanities and Social Sciences,multidisciplinary,Science},
  file = {/Users/sovacool/Documents/Zotero/storage/E69ZXUML/Simpson_1949_Measurement of Diversity.pdf}
}

@misc{sjoberg_ggsankey_2022,
  title = {Ggsankey: {{Sankey}}, {{Alluvial}} and {{Sankey Bump Plots}}},
  author = {Sjoberg, David},
  year = {2022},
  url = {https://github.com/davidsjoberg/ggsankey}
}

@article{smith_enterococci_2022,
  title = {Enterococci Enhance {{{\emph{Clostridioides}}}}{\emph{ Difficile}} Pathogenesis},
  author = {Smith, Alexander B. and Jenior, Matthew L. and Keenan, Orlaith and Hart, Jessica L. and Specker, Jonathan and Abbas, Arwa and Rangel, Paula C. and Di, Chao and Green, Jamal and Bustin, Katelyn A. and Gaddy, Jennifer A. and Nicholson, Maribeth R. and Laut, Clare and Kelly, Brendan J. and Matthews, Megan L. and Evans, Daniel R. and Van Tyne, Daria and Furth, Emma E. and Papin, Jason A. and Bushman, Frederic D. and Erlichman, Jessi and Baldassano, Robert N. and Silverman, Michael A. and Dunny, Gary M. and Prentice, Boone M. and Skaar, Eric P. and Zackular, Joseph P.},
  year = {2022},
  month = nov,
  journal = {Nature},
  volume = {611},
  number = {7937},
  pages = {780--786},
  issn = {1476-4687},
  doi = {10.1038/s41586-022-05438-x},
  url = {https://www.nature.com/articles/s41586-022-05438-x},
  urldate = {2023-03-16},
  abstract = {Enterococci enhance the fitness and pathogenesis of Clostridioides difficile in the gut by altering the amino acid composition and providing signals that increase its virulence towards the host.},
  copyright = {2022 The Author(s), under exclusive licence to Springer Nature Limited},
  langid = {english},
  keywords = {Bacterial pathogenesis,Bacterial systems biology,Microbiome,Pathogens},
  file = {/Users/sovacool/Documents/Zotero/storage/PT52WA4A/Smith et al. - 2022 - Enterococci enhance Clostridioides difficile patho.pdf}
}

@misc{sovacool_mikropml_2023,
  title = {Mikropml {{Snakemake}} Workflow},
  shorttitle = {Mikropml-Snakemake},
  author = {Sovacool, Kelly and Lapp, Zena and Armour, Courtney and Lucas, Sarah K. and Schloss, Patrick},
  year = {2023},
  month = jan,
  doi = {10.5281/zenodo.4759351},
  url = {https://github.com/SchlossLab/mikropml-snakemake-workflow},
  urldate = {2023-03-16},
  howpublished = {Zenodo},
  file = {/Users/sovacool/Documents/Zotero/storage/GMGGL2ZG/7587360.html}
}

@misc{sovacool_schtools_2022,
  title = {Schtools: {{Schloss}} Lab Tools for Reproducible Microbiome Research},
  author = {Sovacool, Kelly and Lesniak, Nick and Lucas, Sarah and Armour, Courtney and Schloss, Patrick},
  year = {2022},
  doi = {10.5281/zenodo.6540686},
  url = {http://www.schlosslab.org/schtools/},
  copyright = {All rights reserved},
  github = {https://github.com/SchlossLab/schtools}
}

@incollection{spackman_signal_1989,
  title = {{{SIGNAL DETECTION THEORY}}: {{VALUABLE TOOLS FOR EVALUATING INDUCTIVE LEARNING}}},
  shorttitle = {{{SIGNAL DETECTION THEORY}}},
  booktitle = {Proceedings of the {{Sixth International Workshop}} on {{Machine Learning}}},
  author = {Spackman, Kent A.},
  year = {1989},
  pages = {160--163},
  publisher = {{Elsevier}},
  doi = {10.1016/B978-1-55860-036-2.50047-3},
  url = {https://linkinghub.elsevier.com/retrieve/pii/B9781558600362500473},
  urldate = {2023-03-28},
  abstract = {This paper describes the use of signal detection theory as a tool for evaluating and comparing concept descriptions learned by inductive inference. We outline the use of ROC curves and describe the experience we have had in using these concepts for inductive learning using connectionist models, genetic search, and symbolic concept acquisition.},
  isbn = {978-1-55860-036-2},
  langid = {english},
  file = {/Users/sovacool/Documents/Zotero/storage/GYRG4H5E/Spackman - 1989 - SIGNAL DETECTION THEORY VALUABLE TOOLS FOR EVALUA.pdf}
}

@article{stevens_validation_2020,
  title = {Validation of the {{SHEA}}/{{IDSA}} Severity Criteria to Predict Poor Outcomes among Inpatients and Outpatients with {{{\emph{Clostridioides}}}}{\emph{ Difficile}} Infection},
  author = {Stevens, Vanessa W. and Shoemaker, Holly E. and Jones, Makoto M. and Jones, Barbara E. and Nelson, Richard E. and Khader, Karim and Samore, Matthew H. and Rubin, Michael A.},
  year = {2020},
  month = may,
  journal = {Infection Control \& Hospital Epidemiology},
  volume = {41},
  number = {5},
  pages = {510--516},
  publisher = {{Cambridge University Press}},
  issn = {0899-823X, 1559-6834},
  doi = {10.1017/ice.2020.8},
  url = {https://www.cambridge.org/core/journals/infection-control-and-hospital-epidemiology/article/abs/validation-of-the-sheaidsa-severity-criteria-to-predict-poor-outcomes-among-inpatients-and-outpatients-with-clostridioides-difficile-infection/F5B2755C406186B46F4966DAA1BCBF25},
  urldate = {2022-01-17},
  abstract = {,  Objective: To determine whether the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA) Clostridioides difficile infection (CDI) severity criteria adequately predicts poor outcomes. Design: Retrospective validation study. Setting and participants: Patients with CDI in the Veterans' Affairs Health System from January 1, 2006, to December 31, 2016. Methods: For the 2010 criteria, patients with leukocytosis or a serum creatinine (SCr) value {$\geq$}1.5 times the baseline were classified as severe. For the 2018 criteria, patients with leukocytosis or a SCr value {$\geq$}1.5 mg/dL were classified as severe. Poor outcomes were defined as hospital or intensive care admission within 7 days of diagnosis, colectomy within 14 days, or 30-day all-cause mortality; they were modeled as a function of the 2010 and 2018 criteria separately using logistic regression. Results: We analyzed data from 86,112 episodes of CDI. Severity was unclassifiable in a large proportion of episodes diagnosed in subacute care (2010, 58.8\%; 2018, 49.2\%). Sensitivity ranged from 0.48 for subacute care using 2010 criteria to 0.73 for acute care using 2018 criteria. Areas under the curve were poor and similar (0.60 for subacute care and 0.57 for acute care) for both versions, but negative predictive values were {$>$}0.80. Conclusions: Model performances across care settings and criteria versions were generally poor but had reasonably high negative predictive value. Many patients in the subacute-care setting, an increasing fraction of CDI cases, could not be classified. More work is needed to develop criteria to identify patients at risk of poor outcomes.},
  langid = {english},
  file = {/Users/sovacool/Documents/Zotero/storage/DF62ACKX/Stevens et al_2020_Validation of the SHEA-IDSA severity criteria to predict poor outcomes among.pdf}
}

@article{taseen_expected_2021,
  title = {Expected Clinical Utility of Automatable Prediction Models for Improving Palliative and End-of-Life Care Outcomes: {{Toward}} Routine Decision Analysis before Implementation},
  shorttitle = {Expected Clinical Utility of Automatable Prediction Models for Improving Palliative and End-of-Life Care Outcomes},
  author = {Taseen, Ryeyan and Ethier, Jean-Fran{\c c}ois},
  year = {2021},
  month = nov,
  journal = {Journal of the American Medical Informatics Association},
  volume = {28},
  number = {11},
  pages = {2366--2378},
  issn = {1527-974X},
  doi = {10.1093/jamia/ocab140},
  url = {https://doi.org/10.1093/jamia/ocab140},
  urldate = {2023-05-29},
  abstract = {The study sought to evaluate the expected clinical utility of automatable prediction models for increasing goals-of-care discussions (GOCDs) among hospitalized patients at the end of life (EOL).We built a decision model from the perspective of clinicians who aim to increase GOCDs at the EOL using an automated alert system. The alternative strategies were 4 prediction models\textemdash 3 random forest models and the Modified Hospital One-year Mortality Risk model\textemdash to generate alerts for patients at a high risk of 1-year mortality. They were trained on admissions from 2011 to 2016 (70 788 patients) and tested with admissions from 2017-2018 (16 490 patients). GOCDs occurring in usual care were measured with code status orders. We calculated the expected risk difference (beneficial outcomes with alerts minus beneficial outcomes without alerts among those at the EOL), the number needed to benefit (number of alerts needed to increase benefit over usual care by 1 outcome), and the net benefit (benefit minus cost) of each strategy.Models had a C-statistic between 0.79 and 0.86. A code status order occurred during 2599 of 3773 (69\%) hospitalizations at the EOL. At a risk threshold corresponding to an alert prevalence of 10\%, the expected risk difference ranged from 5.4\% to 10.7\% and the number needed to benefit ranged from 5.4 to 10.9 alerts. Using revealed preferences, only 2 models improved net benefit over usual care. A random forest model with diagnostic predictors had the highest expected value, including in sensitivity analyses.Prediction models with acceptable predictive validity differed meaningfully in their ability to improve over usual decision making.An evaluation of clinical utility, such as by using decision curve analysis, is recommended after validating a prediction model because metrics of model predictiveness, such as the C-statistic, are not informative of clinical value.},
  file = {/Users/sovacool/Documents/Zotero/storage/P37E329W/Taseen_Ethier_2021_Expected clinical utility of automatable prediction models for improving.pdf;/Users/sovacool/Documents/Zotero/storage/BF5J8C3Z/6362565.html}
}

@article{tashiro_oral_2022,
  title = {Oral Fidaxomicin versus Vancomycin for the Treatment of {{{\emph{Clostridioides}}}}{\emph{ Difficile}} Infection: {{A}} Systematic Review and Meta-Analysis of Randomized Controlled Trials},
  shorttitle = {Oral Fidaxomicin versus Vancomycin for the Treatment of {{Clostridioides}} Difficile Infection},
  author = {Tashiro, Sho and Mihara, Takayuki and Sasaki, Moe and Shimamura, Chiaki and Shimamura, Rina and Suzuki, Shiho and Yoshikawa, Maiko and Hasegawa, Tatsuki and Enoki, Yuki and Taguchi, Kazuaki and Matsumoto, Kazuaki and Ohge, Hiroki and Suzuki, Hiromichi and Nakamura, Atsushi and Mori, Nobuaki and Morinaga, Yoshitomo and Yamagishi, Yuka and Yoshizawa, Sadako and Yanagihara, Katsunori and Mikamo, Hiroshige and Kunishima, Hiroyuki},
  year = {2022},
  month = nov,
  journal = {Journal of Infection and Chemotherapy},
  volume = {28},
  number = {11},
  pages = {1536--1545},
  issn = {1341321X},
  doi = {10.1016/j.jiac.2022.08.008},
  url = {https://linkinghub.elsevier.com/retrieve/pii/S1341321X22002343},
  urldate = {2023-05-29},
  abstract = {Background: Fidaxomicin (FDX) has received considerable attention as a novel therapeutic alternative agent to vancomycin (VCM) for Clostridioides difficile infection (CDI). However, the superiority and efficacy profile of FDX are not sufficiently determined by high-quality evidence. This study aimed to clarify the superiority of FDX for CDI treatment through a systematic review and meta-analysis. Methods: We conducted a meta-analysis of randomized controlled trials (RCTs) which evaluated the efficacy and safety of FDX and VCM in patients with CDI. Electronic databases (PubMed, Cochrane Library, Web of Science, and Clinicaltrials.gov) were searched for studies published until October 15, 2021. The primary endpoint was global cure. The secondary endpoints were clinical cure, recurrence, and adverse event. Risk ratios (RRs), risk differences (RDs), and 95\% confidence intervals were calculated using Mantel-Haenszel random-effects model. The risk of bias was assessed using Cochrane Handbook for Systematic Reviews of Interventions and Assessment Criteria. Results: Six RCTs were included in this meta-analysis. Compared to VCM, FDX was associated with significantly higher global cure rates (RR = 1.18, P {$<$} 0.00001; RD = 0.11, 95\% CI = 0.07\textendash 0.16). In addition, clinical cure rates were comparable between FDX and VCM (P = 0.31). FDX was associated with significantly lower recur\- rence rates compared to VCM (RR = 0.59, P {$<$} 0.0001). In addition, adverse event rates were not significantly different between the drugs (P = 0.41). Conclusion: FDX achieves significantly higher global cure rates and lower recurrence rates and is comparable to VCM in clinical cure rates and adverse event rates in patients with CDI. Collectively, FDX is superior to VCM as a therapeutic agent for CDI.},
  langid = {english},
  file = {/Users/sovacool/Documents/Zotero/storage/7YWSL3Y5/Tashiro et al. - 2022 - Oral fidaxomicin versus vancomycin for the treatme.pdf}
}

@article{teng_clostridium_2019,
  title = {{\emph{Clostridium Difficile}} {{Infection Risk}} with {{Important Antibiotic Classes}}: {{An Analysis}} of the {{FDA Adverse Event Reporting System}}},
  shorttitle = {{\emph{Clostridium Difficile}} {{Infection Risk}} with {{Important Antibiotic Classes}}},
  author = {Teng, Chengwen and Reveles, Kelly R. and {Obodozie-Ofoegbu}, Obiageri O. and Frei, Christopher R.},
  year = {2019},
  month = may,
  journal = {International Journal of Medical Sciences},
  volume = {16},
  number = {5},
  pages = {630--635},
  publisher = {{Ivyspring International Publisher}},
  issn = {1449-1907},
  doi = {10.7150/ijms.30739},
  url = {https://www.medsci.org/v16p0630.htm},
  urldate = {2023-06-04},
  langid = {english},
  file = {/Users/sovacool/Documents/Zotero/storage/JKNI8EZG/Teng et al_2019_iClostridium difficile-i Infection Risk with Important Antibiotic Classes.pdf}
}

@article{thandavaram_efficacy_2022,
  title = {The {{Efficacy}} of {{Bezlotoxumab}} in the {{Prevention}} of {{Recurrent Clostridium}} Difficile: {{A Systematic Review}}},
  shorttitle = {The {{Efficacy}} of {{Bezlotoxumab}} in the {{Prevention}} of {{Recurrent Clostridium}} Difficile},
  author = {Thandavaram, Abhay and Channar, Aneeta and Purohit, Ansh and Shrestha, Bijay and Patel, Deepkumar and Shah, Hriday and Hanna, Kerollos and Kaur, Harkirat and Alazzeh, Mohammad S. and Mohammed, Lubna and Thandavaram, Abhay and Channar, Aneeta and Purohit, Ansh and Shrestha, Bijay and Patel, Deepkumar and Shah, Hriday and Hanna, Kerollos S. and Kaur, Harkirat and Alazzeh, Mohammad S. and Mohammed, Lubna},
  year = {2022},
  month = aug,
  journal = {Cureus},
  volume = {14},
  number = {8},
  publisher = {{Cureus}},
  issn = {2168-8184},
  doi = {10.7759/cureus.27979},
  url = {https://www.cureus.com/articles/103763-the-efficacy-of-bezlotoxumab-in-the-prevention-of-recurrent-clostridium-difficile-a-systematic-review},
  urldate = {2023-05-08},
  abstract = {Clostridium difficile infection (CDI) is the most common nosocomial infection in hospitals. Despite the fact that CDI has treatment options, recurrence is common after the treatment, recurrence will occur in approximately 20\%-35\% of people initially affected, with 40\%-60\% of these having a second recurrence. Patients are more likely to have several recurrences after the second, which can lead to antibiotic overuse, and as a result, CDI-related health care expenses, hospitalizations, and mortality are on the rise. The first treatment to receive~Food and Drug Administration (FDA) approval for the prevention of C. difficile recurrence is bezlotoxumab, a novel human monoclonal antibody against C. difficile toxin B. In the present systematic review, we assessed various studies from PubMed, PubMed Central (PMC), Google Scholar, and Science direct that evaluated the efficacy of bezlotoxumab in the prevention of recurrent C. difficile (rCDI), and we also briefly discussed the pathophysiology of C. difficile and the risk factors for recurrence of C. difficile. The major MODIFY trial has proven the efficacy, pooled analysis of MODIFY 1 AND 2 trials demonstrated the following results as compared to placebo (bezlotoxumab: 129/781 [16.5] placebo:206/773 [26.6] -10.0\% [95\% CI -14.0 to -6.0], p\&lt;0.0001) with number needed to treat (NNT) of 10. All other observational studies also showed a positive response with bezlotoxumab in the prevention of C. difficile. In conclusion, bezlotoxumab is a great option adjunctive with standard of care~CDI antibiotics for the prevention of rCDI in high-risk adults.},
  langid = {english},
  file = {/Users/sovacool/Documents/Zotero/storage/4HMETXYG/Thandavaram et al_2022_The Efficacy of Bezlotoxumab in the Prevention of Recurrent Clostridium.pdf}
}

@article{tixier_faecal_2019,
  title = {Faecal Microbiota Transplant Decreases Mortality in Severe and Fulminant {{Clostridioides}} Difficile Infection in Critically Ill Patients},
  author = {Tixier, Emily N. and Verheyen, Elijah and Ungaro, Ryan C. and Grinspan, Ari M.},
  year = {2019},
  journal = {Alimentary Pharmacology \& Therapeutics},
  volume = {50},
  number = {10},
  pages = {1094--1099},
  issn = {1365-2036},
  doi = {10.1111/apt.15526},
  url = {https://onlinelibrary.wiley.com/doi/abs/10.1111/apt.15526},
  urldate = {2023-05-04},
  abstract = {Background Severe and fulminant Clostridioides difficile infection is associated with high mortality rates. While faecal microbiota transplant has been shown to be effective for recurrent C difficile infection, there is little data on the utility of faecal microbiota transplant in severe or fulminant C difficile infection. Aim To compare the outcomes of antibiotics and faecal microbiota transplantation vs antibiotics alone (standard of care) in critically ill patients with severe or fulminant C difficile infection. Methods This was a retrospective, matched cohort study in one urban tertiary academic care centre including 48 patients hospitalised with severe or fulminant C difficile infection who required care in intensive care unit. Results Patients who received faecal microbiota transplantation (n = 16) had a 77\% decrease in odds for mortality (OR 0.23, 95\% CI 0.06-0.97) with a number needed to treat of 3 to prevent one death. Conclusions Faecal microbiota transplantation provides mortality benefit over standard of care for severe and fulminant C difficile infection and should be considered in critically ill patients.},
  langid = {english},
  file = {/Users/sovacool/Documents/Zotero/storage/PIRID4G8/Tixier et al_2019_Faecal microbiota transplant decreases mortality in severe and fulminant.pdf;/Users/sovacool/Documents/Zotero/storage/WEJIZYDR/apt.html}
}

@article{tomkovich_initial_2020,
  title = {The {{Initial Gut Microbiota}} and {{Response}} to {{Antibiotic Perturbation Influence}} {{{\emph{Clostridioides}}}}{\emph{ Difficile}} {{Clearance}} in {{Mice}}},
  author = {Tomkovich, Sarah and Stough, Joshua M. A. and Bishop, Lucas and Schloss, Patrick D.},
  year = {2020},
  month = oct,
  journal = {mSphere},
  volume = {5},
  number = {5},
  publisher = {{American Society for Microbiology Journals}},
  issn = {2379-5042},
  doi = {10.1128/mSphere.00869-20},
  url = {https://msphere.asm.org/content/5/5/e00869-20},
  urldate = {2020-10-26},
  abstract = {The gut microbiota has a key role in determining susceptibility to Clostridioides difficile infections (CDIs). However, much of the mechanistic work examining CDIs in mouse models uses animals obtained from a single source. We treated mice from 6 sources (2 University of Michigan colonies and 4 commercial vendors) with clindamycin, followed by a C. difficile challenge, and then measured C. difficile colonization levels throughout the infection. The microbiota were profiled via 16S rRNA gene sequencing to examine the variation across sources and alterations due to clindamycin treatment and C. difficile challenge. While all mice were colonized 1 day postinfection, variation emerged from days 3 to 7 postinfection with animals from some sources colonized with C. difficile for longer and at higher levels. We identified bacteria that varied in relative abundance across sources and throughout the experiment. Some bacteria were consistently impacted by clindamycin treatment in all sources of mice, including Lachnospiraceae, Ruminococcaceae, and Enterobacteriaceae. To identify bacteria that were most important to colonization regardless of the source, we created logistic regression models that successfully classified mice based on whether they cleared C. difficile by 7 days postinfection using community composition data at baseline, post-clindamycin treatment, and 1 day postinfection. With these models, we identified 4 bacterial taxa that were predictive of whether C. difficile cleared. They varied across sources (Bacteroides) or were altered by clindamycin (Porphyromonadaceae) or both (Enterobacteriaceae and Enterococcus). Allowing for microbiota variation across sources better emulates human interindividual variation and can help identify bacterial drivers of phenotypic variation in the context of CDIs. IMPORTANCE Clostridioides difficile is a leading nosocomial infection. Although perturbation to the gut microbiota is an established risk, there is variation in who becomes asymptomatically colonized, develops an infection, or has adverse infection outcomes. Mouse models of C. difficile infection (CDI) are widely used to answer a variety of C. difficile pathogenesis questions. However, the interindividual variation between mice from the same breeding facility is less than what is observed in humans. Therefore, we challenged mice from 6 different breeding colonies with C. difficile. We found that the starting microbial community structures and C. difficile persistence varied by the source of mice. Interestingly, a subset of the bacteria that varied across sources were associated with how long C. difficile was able to colonize. By increasing the interindividual diversity of the starting communities, we were able to better model human diversity. This provided a more nuanced perspective of C. difficile pathogenesis.},
  chapter = {Research Article},
  copyright = {Copyright \textcopyright{} 2020 Tomkovich et al.. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.},
  langid = {english},
  pmid = {33087520},
  file = {/Users/sovacool/Documents/Zotero/storage/8LZVMZZC/Tomkovich et al. - 2020 - The Initial Gut Microbiota and Response to Antibio.pdf;/Users/sovacool/Library/CloudStorage/GoogleDrive-sovacool@umich.edu/Shared drives/umich-shared/Zotero/Tomkovich_et_al_2020_mSphere.pdf}
}

@article{tomkovich_osmotic_2021,
  title = {An {{Osmotic Laxative Renders Mice Susceptible}} to {{Prolonged}} {{{\emph{Clostridioides}}}}{\emph{ Difficile}} {{Colonization}} and {{Hinders Clearance}}},
  author = {Tomkovich, Sarah and Taylor, Ana and King, Jacob and Colovas, Joanna and Bishop, Lucas and McBride, Kathryn and Royzenblat, Sonya and Lesniak, Nicholas A. and Bergin, Ingrid L. and Schloss, Patrick D.},
  year = {2021},
  month = sep,
  journal = {mSphere},
  volume = {6},
  number = {5},
  pages = {10.1128/msphere.00629-21},
  publisher = {{American Society for Microbiology}},
  doi = {10.1128/msphere.00629-21},
  url = {https://journals.asm.org/doi/10.1128/mSphere.00629-21},
  urldate = {2023-06-06},
  abstract = {Antibiotics are a major risk factor for Clostridioides difficile infections (CDIs) because of their impact on the microbiota. However, nonantibiotic medications such as the ubiquitous osmotic laxative polyethylene glycol 3350 (PEG 3350) also alter the microbiota. Clinicians also hypothesize that PEG helps clear C. difficile. But whether PEG impacts CDI susceptibility and clearance is unclear. To examine how PEG impacts susceptibility, we treated C57BL/6 mice with 5-day and 1-day doses of 15\% PEG in the drinking water and then challenged the mice with C. difficile 630. We used clindamycin-treated mice as a control because they consistently clear C. difficile within 10\,days postchallenge. PEG treatment alone was sufficient to render mice susceptible, and 5-day PEG-treated mice remained colonized for up to 30\,days postchallenge. In contrast, 1-day PEG-treated mice were transiently colonized, clearing C. difficile within 7\,days postchallenge. To examine how PEG treatment impacts clearance, we administered a 1-day PEG treatment to clindamycin-treated, C. difficile-challenged mice. Administering PEG to mice after C. difficile challenge prolonged colonization up to 30\,days postchallenge. When we trained a random forest model with community data from 5\,days postchallenge, we were able to predict which mice would exhibit prolonged colonization (area under the receiver operating characteristic curve [AUROC]\,=\,0.90). Examining the dynamics of these bacterial populations during the postchallenge period revealed patterns in the relative abundances of Bacteroides, Enterobacteriaceae, Porphyromonadaceae, Lachnospiraceae, and Akkermansia that were associated with prolonged C. difficile colonization in PEG-treated mice. Thus, the osmotic laxative PEG rendered mice susceptible to C. difficile colonization and hindered clearance. IMPORTANCE Diarrheal samples from patients taking laxatives are typically rejected for Clostridioides difficile testing. However, there are similarities between the bacterial communities from people with diarrhea and those with C. difficile infections (CDIs), including lower diversity than the communities from healthy patients. This observation led us to hypothesize that diarrhea may be an indicator of C. difficile susceptibility. We explored how osmotic laxatives disrupt the microbiota's colonization resistance to C. difficile by administering a laxative to mice either before or after C. difficile challenge. Our findings suggest that osmotic laxatives disrupt colonization resistance to C. difficile and prevent clearance among mice already colonized with C. difficile. Considering that most hospitals recommend not performing C. difficile testing on patients taking laxatives, and laxatives are prescribed prior to administering fecal microbiota transplants via colonoscopy to patients with recurrent CDIs, further studies are needed to evaluate if laxatives impact microbiota colonization resistance in humans.},
  file = {/Users/sovacool/Documents/Zotero/storage/CR6N7L98/Tomkovich et al_2021_An Osmotic Laxative Renders Mice Susceptible to Prolonged Clostridioides.pdf;/Users/sovacool/Documents/Zotero/storage/JN4LH8WX/Tomkovich et al_2021_An Osmotic Laxative Renders Mice Susceptible to Prolonged Clostridioides.pdf}
}

@article{topcuoglu_framework_2020,
  title = {A {{Framework}} for {{Effective Application}} of {{Machine Learning}} to {{Microbiome-Based Classification Problems}}},
  author = {Top{\c c}uo{\u g}lu, Beg{\"u}m D. and Lesniak, Nicholas A. and Ruffin, Mack T. and Wiens, Jenna and Schloss, Patrick D.},
  year = {2020},
  month = jun,
  journal = {mBio},
  volume = {11},
  number = {3},
  publisher = {{American Society for Microbiology}},
  issn = {2150-7511},
  doi = {10.1128/mBio.00434-20},
  url = {https://mbio.asm.org/content/11/3/e00434-20},
  urldate = {2020-07-09},
  abstract = {Machine learning (ML) modeling of the human microbiome has the potential to identify microbial biomarkers and aid in the diagnosis of many diseases such as inflammatory bowel disease, diabetes, and colorectal cancer. Progress has been made toward developing ML models that predict health outcomes using bacterial abundances, but inconsistent adoption of training and evaluation methods call the validity of these models into question. Furthermore, there appears to be a preference by many researchers to favor increased model complexity over interpretability. To overcome these challenges, we trained seven models that used fecal 16S rRNA sequence data to predict the presence of colonic screen relevant neoplasias (SRNs) (n = 490 patients, 261 controls and 229 cases). We developed a reusable open-source pipeline to train, validate, and interpret ML models. To show the effect of model selection, we assessed the predictive performance, interpretability, and training time of L2-regularized logistic regression, L1- and L2-regularized support vector machines (SVM) with linear and radial basis function kernels, a decision tree, random forest, and gradient boosted trees (XGBoost). The random forest model performed best at detecting SRNs with an area under the receiver operating characteristic curve (AUROC) of 0.695 (interquartile range [IQR], 0.651 to 0.739) but was slow to train (83.2 h) and not inherently interpretable. Despite its simplicity, L2-regularized logistic regression followed random forest in predictive performance with an AUROC of 0.680 (IQR, 0.625 to 0.735), trained faster (12 min), and was inherently interpretable. Our analysis highlights the importance of choosing an ML approach based on the goal of the study, as the choice will inform expectations of performance and interpretability. IMPORTANCE Diagnosing diseases using machine learning (ML) is rapidly being adopted in microbiome studies. However, the estimated performance associated with these models is likely overoptimistic. Moreover, there is a trend toward using black box models without a discussion of the difficulty of interpreting such models when trying to identify microbial biomarkers of disease. This work represents a step toward developing more-reproducible ML practices in applying ML to microbiome research. We implement a rigorous pipeline and emphasize the importance of selecting ML models that reflect the goal of the study. These concepts are not particular to the study of human health but can also be applied to environmental microbiology studies.},
  chapter = {Research Article},
  copyright = {Copyright \textcopyright{} 2020 Top\c{c}uo\u{g}lu et al.. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.},
  langid = {english},
  pmid = {32518182},
  file = {/Users/sovacool/Library/CloudStorage/GoogleDrive-sovacool@umich.edu/Shared drives/umich-shared/Zotero/Topuolu_et_al_2020_mBio.pdf}
}

@article{topcuoglu_mikropml_2021,
  title = {Mikropml: {{User-Friendly R Package}} for {{Supervised Machine Learning Pipelines}}},
  shorttitle = {Mikropml},
  author = {Top{\c c}uo{\u g}lu, Beg{\"u}m D. and Lapp, Zena and Sovacool, Kelly L. and Snitkin, Evan and Wiens, Jenna and Schloss, Patrick D.},
  year = {2021},
  month = may,
  journal = {JOSS},
  volume = {6},
  number = {61},
  pages = {3073},
  issn = {2475-9066},
  doi = {10.21105/joss.03073},
  url = {https://joss.theoj.org/papers/10.21105/joss.03073},
  urldate = {2021-05-14},
  copyright = {All rights reserved},
  github = {https://github.com/SchlossLab/mikRopML},
  langid = {english},
  file = {/Users/sovacool/Library/CloudStorage/GoogleDrive-sovacool@umich.edu/Shared drives/umich-shared/Zotero/Topuolu_et_al_2021_JOSS.pdf}
}

@misc{van_rossum_python_2009,
  title = {Python 3 {{Reference Manual}} | {{Guide}} Books},
  author = {Van Rossum, Guido and Drake, Fred L.},
  year = {2009},
  url = {https://dl.acm.org/doi/book/10.5555/1593511}
}

@article{vickers_decision_2006,
  title = {Decision {{Curve Analysis}}: {{A Novel Method}} for {{Evaluating Prediction Models}}},
  shorttitle = {Decision {{Curve Analysis}}},
  author = {Vickers, Andrew J. and Elkin, Elena B.},
  year = {2006},
  month = nov,
  journal = {Med Decis Making},
  volume = {26},
  number = {6},
  pages = {565--574},
  issn = {0272-989X, 1552-681X},
  doi = {10.1177/0272989X06295361},
  url = {http://journals.sagepub.com/doi/10.1177/0272989X06295361},
  urldate = {2023-05-24},
  abstract = {Background. Diagnostic and prognostic models are typically evaluated with measures of accuracy that do not address clinical consequences. Decision-analytic techniques allow assessment of clinical outcomes but often require collection of additional information and may be cumbersome to apply to models that yield a continuous result. The authors sought a method for evaluating and comparing prediction models that incorporates clinical consequences, requires only the data set on which the models are tested, and can be applied to models that have either continuous or dichotomous results. Method. The authors describe decision curve analysis, a simple, novel method of evaluating predictive models. They start by assuming that the threshold probability of a disease or event at which a patient would opt for treatment is informative of how the patient weighs the relative harms of a false-positive and a false-negative prediction. This theoretical relationship is then used to derive the net benefit of the model across different threshold probabilities. Plotting net benefit against threshold probability yields the ``decision curve.'' The authors apply the method to models for the prediction of seminal vesicle invasion in prostate cancer patients. Decision curve analysis identified the range of threshold probabilities in which a model was of value, the magnitude of benefit, and which of several models was optimal. Conclusion. Decision curve analysis is a suitable method for evaluating alternative diagnostic and prognostic strategies that has advantages over other commonly used measures and techniques.},
  langid = {english},
  file = {/Users/sovacool/Documents/Zotero/storage/DXXKM3ZK/Vickers and Elkin - 2006 - Decision Curve Analysis A Novel Method for Evalua.pdf}
}

@article{westcott_opticlust_2017,
  title = {{{OptiClust}}, an {{Improved Method}} for {{Assigning Amplicon-Based Sequence Data}} to {{Operational Taxonomic Units}}},
  author = {Westcott, Sarah L. and Schloss, Patrick D.},
  editor = {McMahon, Katherine},
  year = {2017},
  month = mar,
  journal = {mSphere},
  volume = {2},
  number = {2},
  pages = {e00073-17},
  issn = {2379-5042},
  doi = {10.1128/mSphereDirect.00073-17},
  url = {http://msphere.asm.org/lookup/doi/10.1128/mSphereDirect.00073-17},
  urldate = {2019-05-16},
  abstract = {Assignment of 16S rRNA gene sequences to operational taxonomic units (OTUs) is a computational bottleneck in the process of analyzing microbial communities. Although this has been an active area of research, it has been difficult to overcome the time and memory demands while improving the quality of the OTU assignments. Here, we developed a new OTU assignment algorithm that iteratively reassigns sequences to new OTUs to optimize the Matthews correlation coefficient (MCC), a measure of the quality of OTU assignments. To assess the new algorithm, OptiClust, we compared it to 10 other algorithms using 16S rRNA gene sequences from two simulated and four natural communities. Using the OptiClust algorithm, the MCC values averaged 15.2 and 16.5\% higher than the OTUs generated when we used the average neighbor and distance-based greedy clustering with VSEARCH, respectively. Furthermore, on average, OptiClust was 94.6 times faster than the average neighbor algorithm and just as fast as distance-based greedy clustering with VSEARCH. An empirical analysis of the efficiency of the algorithms showed that the time and memory required to perform the algorithm scaled quadratically with the number of unique sequences in the data set. The significant improvement in the quality of the OTU assignments over previously existing methods will significantly enhance downstream analysis by limiting the splitting of similar sequences into separate OTUs and merging of dissimilar sequences into the same OTU. The development of the OptiClust algorithm represents a significant advance that is likely to have numerous other applications.},
  langid = {english},
  keywords = {Schloss\_Lab,Schloss\textsubscript{L}ab},
  file = {/Users/sovacool/Library/CloudStorage/GoogleDrive-sovacool@umich.edu/Shared drives/umich-shared/Zotero/Westcott_et_al_2017_mSphere.pdf;/Users/sovacool/Library/CloudStorage/GoogleDrive-sovacool@umich.edu/Shared drives/umich-shared/Zotero/Westcott_et_al_2017_mSphere2.pdf}
}

@article{wickham_welcome_2019,
  title = {Welcome to the {{Tidyverse}}},
  author = {Wickham, Hadley and Averick, Mara and Bryan, Jennifer and Chang, Winston and McGowan, Lucy D'Agostino and Fran{\c c}ois, Romain and Grolemund, Garrett and Hayes, Alex and Henry, Lionel and Hester, Jim and Kuhn, Max and Pedersen, Thomas Lin and Miller, Evan and Bache, Stephan Milton and M{\"u}ller, Kirill and Ooms, Jeroen and Robinson, David and Seidel, Dana Paige and Spinu, Vitalie and Takahashi, Kohske and Vaughan, Davis and Wilke, Claus and Woo, Kara and Yutani, Hiroaki},
  year = {2019},
  month = nov,
  journal = {Journal of Open Source Software},
  volume = {4},
  number = {43},
  pages = {1686},
  issn = {2475-9066},
  doi = {10.21105/joss.01686},
  url = {https://joss.theoj.org/papers/10.21105/joss.01686},
  urldate = {2020-08-26},
  abstract = {Wickham et al., (2019). Welcome to the Tidyverse. Journal of Open Source Software, 4(43), 1686, https://doi.org/10.21105/joss.01686},
  langid = {english},
  file = {/Users/sovacool/Library/CloudStorage/GoogleDrive-sovacool@umich.edu/Shared drives/umich-shared/Zotero/Wickham_et_al_2019_Journal_of_Open_Source_Software.pdf;/Users/sovacool/Documents/Zotero/storage/RHA4K7MW/joss.html}
}

@phdthesis{wiens_learning_2014,
  type = {Thesis},
  title = {Learning to Prevent Healthcare-Associated Infections : Leveraging Data across Time and Space to Improve Local Predictions},
  shorttitle = {Learning to Prevent Healthcare-Associated Infections},
  author = {Wiens, Jenna Marleau},
  year = {2014},
  url = {https://dspace.mit.edu/handle/1721.1/91103},
  urldate = {2023-04-11},
  abstract = {The proliferation of electronic medical records holds out the promise of using machine learning and data mining to build models that will help healthcare providers improve patient outcomes. However, building useful models from these datasets presents many technical problems. Among the challenges are the large number of factors (both intrinsic and extrinsic) influencing a patient's risk of an adverse outcome, the inherent evolution of that risk over time, and the relative rarity of adverse outcomes, institutional differences and the lack of ground truth. In this thesis we tackle these challenges in the context of predicting healthcare-associated infections (HAIs). HAIs are a serious problem in US acute care hospitals, affecting approximately 4\% of all inpatients on any given day. Despite best efforts to reduce incidence, HAIs remain stubbornly prevalent. We hypothesize that one of the reasons why is lack of an effective clinical tool for accurately measuring patient risk. Therefore, we develop accurate models for predicting which patients are at risk of acquiring an infection with Clostridium difficile (a common HAI). In contrast to previous work, we take a novel data-centric approach, leveraging the contents of EMRs from over 100,000 hospital admissions. We show how, by adapting techniques from time-series classification, transfer learning and multitask learning, we can learn more accurate models for patient risk stratification. Our model, based on thousands of variables both time-varying and time-invariant, does not remain static but changes over the course of a patient admission. Applied to a held-out validation set of 25,000 patient admissions. our model achieved an area under the receiver operating characteristic curve of 0.81 (95\% CI 0.78-0.84). The model has been successfully integrated into the health record system at a large hospital in the US, and is being used to produce daily risk estimates for each inpatient. While more complex than traditional risk stratification methods, the widespread development and use of such data-driven models could ultimately enable cost-effective, targeted prevention strategies that reduce the incidence of HAIs.},
  copyright = {M.I.T. theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. See provided URL for inquiries about permission.},
  langid = {english},
  school = {Massachusetts Institute of Technology},
  annotation = {Accepted: 2014-10-21T17:26:14Z},
  file = {/Users/sovacool/Documents/Zotero/storage/DLETIB4E/Wiens_2014_Learning to prevent healthcare-associated infections.pdf}
}

@article{wiens_learning_2014-1,
  title = {Learning {{Data-Driven Patient Risk Stratification Models}} for {{Clostridium}} Difficile},
  author = {Wiens, Jenna and Campbell, Wayne N. and Franklin, Ella S. and Guttag, John V. and Horvitz, Eric},
  year = {2014},
  month = sep,
  journal = {Open Forum Infectious Diseases},
  volume = {1},
  number = {2},
  pages = {ofu045},
  issn = {2328-8957},
  doi = {10.1093/ofid/ofu045},
  url = {https://academic.oup.com/ofid/article/doi/10.1093/ofid/ofu045/1462831},
  urldate = {2023-04-11},
  abstract = {Background. Although many risk factors are well known, Clostridium difficile infection (CDI) continues to be a significant problem throughout the world. The purpose of this study was to develop and validate a data-driven, hospital-specific risk stratification procedure for estimating the probability that an inpatient will test positive for C difficile. Methods. We consider electronic medical record (EMR) data from patients admitted for {$\geq$}24 hours to a large urban hospital in the U.S. between April 2011 and April 2013. Predictive models were constructed using L2-regularized logistic regression and data from the first year. The number of observational variables considered varied from a small set of well known risk factors readily available to a physician to over 10 000 variables automatically extracted from the EMR. Each model was evaluated on holdout admission data from the following year. A total of 34 846 admissions with 372 cases of CDI was used to train the model. Results. Applied to the separate validation set of 34 722 admissions with 355 cases of CDI, the model that made use of the additional EMR data yielded an area under the receiver operating characteristic curve (AUROC) of 0.81 (95\% confidence interval [CI], .79\textendash.83), and it significantly outperformed the model that considered only the small set of known clinical risk factors, AUROC of 0.71 (95\% CI, .69\textendash.75). Conclusions. Automated risk stratification of patients based on the contents of their EMRs can be used to accurately identify a high-risk population of patients. The proposed method holds promise for enabling the selective allocation of interventions aimed at reducing the rate of CDI.},
  langid = {english},
  file = {/Users/sovacool/Documents/Zotero/storage/YIRG2XCX/Wiens et al. - 2014 - Learning Data-Driven Patient Risk Stratification M.pdf}
}

@article{wiens_no_2019,
  title = {Do No Harm: A Roadmap for Responsible Machine Learning for Health Care},
  shorttitle = {Do No Harm},
  author = {Wiens, Jenna and Saria, Suchi and Sendak, Mark and Ghassemi, Marzyeh and Liu, Vincent X. and {Doshi-Velez}, Finale and Jung, Kenneth and Heller, Katherine and Kale, David and Saeed, Mohammed and Ossorio, Pilar N. and {Thadaney-Israni}, Sonoo and Goldenberg, Anna},
  year = {2019},
  month = sep,
  journal = {Nat Med},
  volume = {25},
  number = {9},
  pages = {1337--1340},
  issn = {1546-170X},
  doi = {10.1038/s41591-019-0548-6},
  url = {http://www.nature.com/articles/s41591-019-0548-6},
  urldate = {2019-10-14},
  abstract = {In this Perspective, the authors present a framework, context and guidelines for accelerating the translation of machine-learning-based interventions in health care.},
  copyright = {2019 Springer Nature America, Inc.},
  langid = {english},
  keywords = {Clinical Decision-Making,Delivery of Health Care,Health care,Humans,Machine Learning,Research management,Scientific community},
  file = {/Users/sovacool/Library/CloudStorage/GoogleDrive-sovacool@umich.edu/Shared drives/umich-shared/Zotero/Wiens_et_al_2019_Nat_Med2.pdf}
}

@misc{wilke_cowplot_2020,
  title = {Cowplot: {{Streamlined Plot Theme}} and {{Plot Annotations}} for 'Ggplot2'},
  author = {Wilke, Claus O.},
  year = {2020},
  url = {https://CRAN.R-project.org/package=cowplot}
}

@misc{wilke_ggtext_2020,
  title = {Ggtext: {{Improved}} Text Rendering Support for 'Ggplot2'},
  author = {Wilke, Claus O.},
  year = {2020},
  url = {https://CRAN.R-project.org/package=ggtext}
}

@article{wu_improved_2021,
  title = {Improved Pathogenicity Prediction for Rare Human Missense Variants},
  author = {Wu, Yingzhou and Liu, Hanqing and Li, Roujia and Sun, Song and Weile, Jochen and Roth, Frederick P.},
  year = {2021},
  month = oct,
  journal = {The American Journal of Human Genetics},
  volume = {108},
  number = {10},
  pages = {1891--1906},
  issn = {00029297},
  doi = {10.1016/j.ajhg.2021.08.012},
  url = {https://linkinghub.elsevier.com/retrieve/pii/S0002929721003207},
  urldate = {2022-11-06},
  langid = {english},
  file = {/Users/sovacool/Documents/Zotero/storage/RNSDE3SK/Wu et al. - 2021 - Improved pathogenicity prediction for rare human m.pdf}
}
